var title_f23_51_24368="AML FAB M1";
var content_f23_51_24368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute myeloid leukemia (M1)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with AML (FAB classification M1). (Wright-Giemsa stain). The majority of cells have a rim of pale to slightly basophilic agranular cytoplasm. The nuclei have finely dispersed chromatin and prominent nucleoli.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     (From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.)",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24368=[""].join("\n");
var outline_f23_51_24368=null;
var title_f23_51_24369="Hyperglycemia treatment for hospitalized patients NPO";
var content_f23_51_24369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperglycemia treatment for hospitalized patients receiving nothing by mouth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 559px; background-image: url(data:image/gif;base64,R0lGODlhvQEvAsQAAP///wAAAIiIiLu7u0RERCIiIt3d3TMzM5mZmREREWZmZu7u7szMzFVVVXd3d6qqqqCgoODg4NDQ0EBAQPDw8GBgYBAQEICAgMDAwAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAC9AS8CAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+7kBgYKDhIWGh4iJiouMjY6PkJGSk5SVlpN/VgGZnJ0jm55RoKGke6OlTKeoq3OqrEeur7JrsbNCtba5Y7i6PbxBAgQywVoEAisDvMZiycDCSL+9OqrJBiIKzzDNxCfEyy7cLwEDIuMt5izexwDfKdvZJO0n8lLNQOE56CnR0jjUAdYAYKuBj0TBFgdX6HOxkMU3eibsoYAYbx0ViT4S3uo35F/AgQMSBEiAAIADQQwE/xQQeWBBNUEKEMAEoE6mIAMCAhVgQFMQvGQHAuwEUEAnAwU3zTUI1BLoyKM3RxywCKCBg2A2AyAgEDSAghIDigaiKUzsUK6BvoYNhCArgrVaTaI0yJSn1gJfRThNwDOnUAYPEpBgEGDBiL0MECQwLOAAgABdS8IteVeBga7jghkwl8ylWAGX07ITS6BoAmvjNjM1TIIfxxr/BglLcEzxggAPRqhcsKCAgHclZC5QN4KAAgZ8TTYgTA5fMp4NGpAo4OAxOeuNDU9NRs649RIOpHvnS5ydsGokaAMAPoI6O+mEkZcMzG4dSQD0cZuIL1BYAOkkcMfOccmFd1tiBeAEoP9e5nhXQEkPPnaMAILdlx+ADTiGnTAKfNUhAOqJ0MBXBvBFgDAykePbdyJslltrrwXh0TUEbBYQQCp5NdwzxrGHAGY4CbPMAgd8lZVQCBQggnOg7IaUaOiM82Ra9nzYUGAINEZfecvYOIKX7yww5VffaEWIAV2emaMCrAGQpF5KNlRlTIMoOdUBCCjQAFVzkvWAkt+9NMhm10W44XqnAeSlCGKxtYw9y4zDAAGClARjjD/M2B+IEy42AknElPjWJo0xWt0DOAopAJHrIMeTCPw18BMoRQoHQJGPvZhZS4eBYuWL6Z1GoXTeVFcfAIuKoF5OZNmK6zKoihqPsfeZUC3/ALH6d12v1xD46pIJfJVActwK9NUCCUxVDjkOKHkti9FhmxmPBwAYYlV5ifAoKJEOoIBjt1n6CaaZggUQjYiOhAC6q/n133qbIOeVX0UFWZ/Dmc305AGzMmVAaEJ5GAihVVXa55MBiShMwGS56egxyboMGak1doUXO4IcA5eSNr1lFsOQtdkTZHZty2C3Q3slL7uAlvuhSZ4+phM5O7PIQFFFDcANqteFFAhoQO6r7zHjeF2UwOUQ7INrKmg0BEZq99BOQywQlnLLRLAd9zk4uC0E3HvngGqbdKOQzNcklAjsRoHn0/jjTegN+QmST265DZVfnvYdhcNAEQqdB/H5/zDw7GM0GplrnjoZobvQLwutx+D32DrMvm4LgJOwlKdBMUCYT6+O6YvmM6y+y+kyjG5C7D4oD4PtLN6w1MO9E+YYUDhPGEDpNxg/ufcl+HWAXZElLgivhzWKbFdfqVQUrxQzwN1dRkU/WiCljWRN/CUjrlQggjFL0cCDkoEQhTJJUgBcaLaez0ypJPJQ1wisopqgzS9LPiFBeAzimJnFxWvvaoZiEDdBoWilepABwG0S1bSK7QB8j4MhrALAk4EEYEJNM9/iElCdZowIWeRJELoQ4CrlJIMqRKnOQk7kMhUJoIjhUYk1+iVFE7hnHDaJE7AMGKGHgaiHDLzXCP51rP8RbHA833LREZeGNxHQZyB7khBN3FWbqEGMHcYqwVICU4Ci+C6FMmkAqha0xxcSTwYydBOgwvKdN41gUpX60sGa0SitcONBRyqAPcQ0kyXqjF8CyOTT+vU0FQqvIWsS0zO6SA4w0SxZFNJJGd0IqgPQB5JssYcj8XGbBxDAAYoZYJIWdbCjDSAoBPhWyVKCkt8FogEL2EwLi+m4Q8IgkdlqZA7JyLJPaQ9fBlklEcl1R5dp5yueLKcxirikAvBmRZlJkAichU7kKStLSgoJZa6zrDCuw0UmURI9xoWTBEiHm1qxRzZ1RxLkCEabnKKJHTHywxLypCt/1FBxbtgT7mH/zprX5IH4hJlDs8VlBFncBMhSxaiSOEyBoADZzdIJKe2lhUgjgWd3ACjTepIAaC0xwPvug46UtsxrN6SUUASKRFmp8IMiOZtENlY6Cp3zdm8CIdqaodShWFReNLSeCYTHg0TuzawizaEfVALSzbUVdlXwSwLsiQe50tVyaFVbXt+KV77C1a+ADWlgQYeEPynzB87rQu5iwLwtCHVxeRssYY9QAMi2zaMOQeIPDsIe6EVEFYXrXGMTm4PFmtaOkZXs8o7woyKQ9gZu86w7XCPauy5hsSvAEyxUu1ojKCCPSiWAS8Zx0pahRWkjOFB6fMk+feFvuKaZXh7LUb4V2Qgm/8HIiUwqqABiaJUdza1gU0A7AMRMSaj1GweRpDM99I1tAUp96Dx9hc7ywQVsosluncQ73Dm+jzUbNMJeMTXgeVhqN6xaYzjNA7G7TUWo42RwNRC8HXMUAEWgxSFRYMbSOVKNgS1Tj22YiJ4W4QZuZWuQT6ejxAeoKzu3oooxOmMCmSCNo2y91w9LlBJNllOSD9iGEKu1ld3y9lKutdTTBABTExAnZuFRwJ8EIB4OG2DJTT4WisnxJut2mBudrVExAZImA+AyoeTtkzk4CaV0XWMQ+TrWScRoY3NpM1mVzNIzFKpUNOPNUEUW8JGRTITftvOdv3HFk6mJrQQoqQHqKf8zgn1T0x9jVaDtw5GGwEyqTc+mU/C1MkJHVYIU3zg39HzMj4QBYxO0w269+hiuzPEmHceZ04YZNXsMFeAiFPg1vw6ORoPb3/CpClmMjmi0juUlYld6y4qE2MzMLJLu7jli1fauSO5TZpOSujXlpa9ARmazehKpJdMrbn0Oh9yNpsunWRXJDVdqMRUGRZNR9fMlLaVbQQ/arUWo7L+/EBKhdWTgjymsVxGehcdCA+HBZrgtIi4Nikv8FRbXRcYvjoqNT5zjg/X4LEQO8k6QHOMlB+zJWXGJlrv85TCPucxnTvOaKyLlgV05zndOB53z/Odv8DnQh64GoRP96GUwOtL/lw4GpTP96VtwOtSnrgmqW50UUr861m3O9a57/etgh4TWGTd2LWS95Gcve6nVXjC2YyHtHIe72+Uucbqr3e4Qd/vb9Y6DCEhgcxKIAN+d4HfAC37wMaBAACYAgQBAYAIBoADimaB4xjse8pKfPAwqQIgKaJ4JnB+E5z//AgkQ4u+kT4LpB4H61LcA8oGYgOuVAPvFz94FjQ8EBG6PhNw7nvctsEAALAB8JAif+MVfwQUCcIHkG2H5zXd+CiIQgMNLXwjUt/71TYCB7ROh+94Pv97DTv7yU4Jz5k+/+jEBCMni3ZAMf//74zD/aua9/SHnXN27UP+g6z/+/Od+/3d//1EngHbQfwNodkeAKoRwWDSQE5olb0KxDksBKH5hcEZWBzp3EoMgXzUgMdtzN860PS8iEhiSQk4gf0mwQjpwGySUHoWRPf1zDGKBgf6mgVAwSLVzDKgCD2IVGuQgb3+EgpETgEjAgj1BLDd0El1RHQswPQIXPhxVAiJhGOgiGLvjG+MSg8zycAeYg15EKcdAKQwQFF2RG7hUIycgExolLxrSgyAyEtHBEk+ggkc4EiJwhb0hGCdxDEExAHskTU42hTDIGlW4FH7hAFXYE0mAgB/1BDqIH5CxGcLQOyUSQIshE3FGS4TohjPkGCLhFznRhktgh0eAhCWzFNXRhyUTGP+EYHAQaC0xiC6PhhtLUSIxWIoJyASRSBT/oR+9E4cjSIRv5kWPhII6WIV9JFYpaISniIczNDJysSp+tBRoI4URGINi2IqfEoPLloE9B4YLQjEi0DvJoCQrcTclFADT9YnrYw6L6InNiH/P6IFBASBzxhYqlG4e6IIARIWCYCiFpCwx6ACbmFo4CInGyDDrEBRRxRNntiD9MxfRiD+vEo/MWIT02AR/KAKsqAQHYFttl5BUcIVSQUN4YIpMgD0e2Yly4IiwYQU5kUfBuIt7l39fCIAb6VcwSQM92QrO2D0iSQS4dZMkSQavZWw8UJSMFZSzdE3hllmkgwzkdQNlKBr/JJAVK4IzAUEp6khoQCk3SMSUJ0CWiRVmE6FZLMAej1iA+TCUtCM7mFUunwCXKoAA1cEfKGWBkcaOyJZsYPmSzTOWlWOWaokC3CBbuJNIKnksHlQSI3RDXLRPQvZfWVkpxlAaIGMkMMFdm9lAgkACD+QppfKYoKluyYWSe6kbjnEii+EAXsmIa5eTL4AYCUMSbtEeU0NcGPQX/GUW/cMr6UYVEiQiDiAoE9NHQVMRj1E+HEhDkwkcx3WQf+WWxUE2GvZLYyRO1iFkBjBEWVRGXGENO0ZOwsEN5Ykcn1RqhQIhlNEpIDIfHlgc7ehId2QcBKAY2yWbgUl/MSAg41FH/6FmMAxyDFC0IGrUJLwyFVUkD2ckLvIDYlI0RMyJY1q0nS0lnecBmArhlK+TVch0FNxpavtWAg+xDnn2IzdxSYOwn9DmJ4DCGQBxJj+FK8HRNKViHIFUYpRjk1TZLcSEJoR5NDJjFH32bVPiFaNEFViiJYKBlgdUoVymJKkUnQxUZk25kx+aQyPCVvrUnSBmKPQZlxVlKpKIExpSphHVhZ/wIugiQebQLvFZlu+ymhIFQeISbtbwjQNDmy7QJ8uyGNoZIDGoUOSka1zoXpOGRAQ1LHdUKn+GNluaHviEKKS2aF/ZoVpKNlOKM745VJQZptfYM99AbxQDEBJjGUBiE/9BUQIoAzWsEZBUA5xjBGeXqROW4h0MYg0G2VtHuZhI8109k1z3JhEv5W04VYtsgVOO1lQr80HYNjHceZ3aBFTRBKrSaWVZap10MDd2qQMh6avhqJPcKgeDU5dQ8JOItH87yVfquq0D15ju6qO8Ja9HgF6HuQYa8a6CRQKGlTff6jr5SgNJCX/lagOkRQywaWnicDogE7CUQ1eNpRuYxa/iYEW5QZaYE5VONpcpULAtALJSqQL2agRxBBunw1Z6IpS1U7G72Fq+dleKGZc7ILIr4Dwl+12Z2TTw9Y/L4DBC0lxYUSkq1RUNwF/mFRWwEi7hSkCBIKIt1bMjcV4CBKb/DtkX9QO0k/WrhnZHn3kCIANGV5s4mBGVm8lddEE0zamPxmAbNEGKerFtEBQMeBFJ8pAVJFK2wTlcV5sVwfCP/Vl1JyBignoAd0NjY0MYueENG2oxYuNUJZCg3bFij8QxYnY3+oEwB4S49pNEYDq5B8ocbTSbv5qfR5OeJxAvyBFuk6s7z2Bq6VkQ/GFD2UmD7jm4AjqeotmaaikcGbIuMFZhrbsvNmivQQoRczaGoWSBx2YjxEFJAnNmSEq55XgMCrAS4VMUbDKZcqEea3ZKHNshmbRLLuun7GAplNSiJ2Ao+dkn7WEpppZnBeFIjERrTAWjYDtmQgousnS3QGIo/1ICZ33yDclLugqIuxI1oCdgN+uEkk4lacfmQ9mAqKdWAhxjb+5FqV56LXajH6lmaubCTvICHeXLtcbiQ5soRqoLwqVUFfABu7dGitlkv8fypqCWHqCWJrkhp/LgHtGywlrjXgM8XbDWpwcbtwrzlNKmNMvwJBfGbCwlNiDTAN52MtIIK5/RGK9ireh1ACTBbiIDEOUGpkjzUuMGGSU8riilIc1Ab8ghNGFbTi18NTNjtkCSqmk7PhBFwJ5ysocht+KpE/erGzqBqljzP7kkbj0zE4FbBQWmph1nk1GIAlfBBUOCWkBQxP7glDmgVIYrCxbLECbwr2VwrkSZMwZ7wP85R6+qVbIgFcp8Q66q7AJDlACWNQM2yxAQOwOEkRM2SLKsXAoOh5Cz7AIOYJDtSLADy7It2w2/RZ2a+qv3IG+6JaYOI5FfMlc+ADgaUXDEnAWVcxmX0cnLvLFEEJJ6DK9hKQQqcR29as1KIlRI5Be7/IBz2W9kV8zJE17NVZxVMV3TuWEqZMsB/Zn6ZQDDaR0G9EtTvLfnKIeBUB3E8EDdE8wsEMcH/SnXGKXtJCLUSTdVq7U621zN8JzOFBPytg695lzbM1zJsNEX264xQGIAkZ4PCiLKRNMG8CZvQgAvzACx62MUMkWcaiM2Arlvqx2JpiIYNrpk1JZqPAOqO1f/7Ww+zSEa8NxoeYKVnctiihtiudu4zZC5eDOoKAUPFJZo5RzN+jzTVpZnTWpL81lm6HJMc1sOSdKi3LCk32EM7ywwSZplYkMMsSQUFW2+McC+emYtgP0V1szIy3M6bOYV5Hu8ViZkOgJmITpP8IBlGsvW4HwDZQbJjWpQJqqtjfFQ0FLTt/YMixooK0HCrNkmz/ZK+iGnUL3OUv3CWsM9imgpP5TVJHs69JRNgTqgNoIRtaRHebHSi/rZwCzTnmNl9FYVz3qNWHob69BnMAMk3IBTE8giF/yOD5Nu3zbYQiLIhy3NMIDRHlXY1TwIbIWYkE3eN+PE5wHI3VYY1LwA/6naVa+CzywtXNC9D5wMBd6sxCzQG2hT14LL3mgAyTqQ4Pkc2lVwAMC11uWAP+ABt6Jg0WHgyZl6A8N8cNL9yiCucgfeVrBcnfG64iiO2G69YAxiyqKt4cVTzzHQy7nYoyduTS0O2i9QHksCD7Y0yQiL44ik493w3s8c3UfM4imuAvKAD3iJl+QsI0z+AujsgI1MBUEeBmFu4LMVXRFtXDa1PR/Lz6Lhz1YRD821IujCXKJh0MZQ06gsJTziAA3dXtAF0X450ZEkyoCwfoZ+6GMh473C1C6D5qLrNjpt0+IBofHQuDwtUD8d1M1xGo45AEZd09kQvEtNFE2ND08dy/+qw3O8UNtoTr4f+9YtGtf0wZw2Ute6VSZ5XSl7nRev49eODdgCDEqPymryplZQfjljDgerLuzZulDzYGWkLSymTesHk9q088OtfWi9wakNlBxI3WrqtJ6acdvGTuapvnPLTjvZesbj/ezIJmtR4VTdRK1eot0szVGm+gzgrVPl+Ax9bjLMfqXqTejnjnPvmuAgy+A/pc0aWfAp964YTq0MweEa5OFe6PBox64YD3LJfgYdPwUf3wYhzzqHNPK0oPHIruoo31fovvLfo+qIHvMyn+gbL36pbPMJh/Nro/NGzPPT4PM5D/T2p/MmL8s4X/QEGH6Fl/OBJ/QysPSg0PT/21d5jfd4kef0ibd4VY954Rd6gjB6WL95nSd+qycIrRf2LlD2gXD221d7sof2MeD2OO97uwf3MED3On98di8Deq/z0Lf3MfD3Op99gA8DhM/z4Ff4L5D4it/4MTLzkB/5MufIkl/5lo8IQ494WYf0eQBDnO8Jm192nk96oT92o/95pa91p695qX91q38EVJYDfqwC0lIDuWyUUmDyrwPh6twCmOGxKTD7FDIDc6WXKNC1tq/kP66LMDAlTTuxKZCYwJ883F6brmEPGlvgvV88iASRHLoCtowDhPHL5kP+AssGrd8CT4MUXj4DMzvdXa0Cn6392t+vuU3Hh0kYRf6X/2oOAkMRBIJBBgRwLoALHM4SjMQANCjuuMmAHACO4GF0ELwAQNfphigoEyRkLnBovQgHkmK1DfAEI+v3ARCREMk1u+1+w12BOL1uf82TjBGyrei6NPAEDDB8NeCQJAAIkBwwAGhxnXAJqEgGdCmoABSoVV0lKaCoESARJg1IJagVIJ0YjBUMWNEwUFotyNJ6cTEWGOmSQN3d5RW3HQeiYK01Kqq9PAQsHLFNLzwEvcw8qKodKEwnuQIwUDvwxACACRG7CAA2KUER8MCHWmep0Bo0IDLwIcbACSSbALAC8GARsobGHEK0oywRiWaiADFSQUjAtl8GXJyDdJAAvwAGLP/Bu1TSwMFOCDi20LdGQRBT7G68SIAEQQJdr0zyOhMA0r8XJ7zl4dWgi4EEDAYuYBU0IpyJECdWodZGkAsEc8QMo9cOLA0hiKRRQwlDwIIcBwbMgMRxbbdzLhychScP1ZMzWwgwGIUCY6SfsaIReMkJlSVcJD5SjZzEquTIWJn5wciVkD8rCP686HumnmG1KG3CaulJsK8XAqSUtYmKiUk5sQwHDSqGAQFSueeMSaPW09TKayg3nLinhJsEZiIlTvCRQN6C0iMhkikkCNe4LxQ0wGZIxlBsc9cmWSKn1DscCmC2QW2y6LkBahmrSGh8P/L9ydcs1wcboAEwykez/TL/EEhD4XBJaducVhoU38C3xlHuFHZTEjox0hMBXTRiAC0tBBUOTQDMgMCIQrmXxHAqauUfHpX118Y5KDRgwI0F6OTVFDtyyOALXDmn0CJjPJLICN4sMld3QtKGxTNFRDIMUaQkIR9BX4Sx2A0ooVGWjBHVOGYdZQ6IQpI3PRNAKYow4ggkWgaUSYQrmBSLFQllFY0LvdFAmoYvqBJAQrTUYkA1NCBqhYhSjIDAorPMYcAXJr04qZlonmmmpxEpcM+no3rKKanHnZpqqsWpSpWpcbza6phN+SmrrcXEmmqut/LqBqu9PiTZrsASW+ymxqKKrLLL0tgss89Cy9+zw0Zb/y2x1CZ7h00Q/ZoSRALUau2gxWJbqqzdGqeWuJ6qK4ez2grYELrt2qHNUgdAFhG9baDLhmw4IXjttDKaxgmh5caxr6s4lcpwZPQi7G4x2zo0r8HFUFKZwmv068ZsAQMbsYwiu3gxxyS3sXG1IOtrssi5YtKFj5lEMQUuV7DaJj+rqOEACrd80YW9WuR7Bs8ZhfiCzyTcmAlrpVgCTFguLKQHNaawdsIX4dqKsnG5Ph1J0Li8ZzItWzjFUwtz1eLmaGmw84QCYX5FwDwjhmlC0JGMQcAI16FSBUNdDdYLCTeAssDZhgb2M6CD4+mI4rU4FScJLr9rB3XmQOnVAvawcf9UcfVlhNBOPQXwXItNQcII1xyqLYbD7KhO74lEs5hEXE+chMi/ciAhhsDMUnv7SgV3kgYtN3zokvPMvYaQGlUHcFYCPPCCEmigcRgIU06RpAQq5WxUQNFreN7ANhvlI8DykXSByopuiI7Kh6RDnHkd27oJBAoi/oUBvPGNMkTTmNqw4yQjUIAwsEQ/BGLKZL/IxAJMAxtB5S4JRzjAZxqAhN9pSDS98pr+6PCasGgJeanIA2gs8QBiyM8kKHgMKmDBIjBJJ08ITB4pbBKUfxEIfZc6jBwGwJpMBAU0s/FZ90ACKDclUQEGxJywkGGTacSCB1gc0h+CkKLRMagB+Qn/Xk9ygoCl2IFDr6mgBM04lws5AIPzc00CupCAysnmOXxpz61IWMU7wFFQsDgPvaKIogToAxVxlN5kcKLGuv3pANYTEBqzgIQfnsI+5mNDAbQ4H4CwrxmGTJ3V8nWiL7JQASFpULZcZUUUBG8YJgFUARhQqEixSjAH2JmhJAWbK1jqf3AoVELoFRXJ1WkTw8Cgpl5AukVmSDDzECGv/GiZVwYqQ7BIZiFTeZcysmMYNwgTFGbjoxGUTiGzKVQJgvkYH+bhd49zkSx1NIIRII6ALtheGgpHKEhB0Zu6pOI112XQg7LBmq4sFsVYljA+qoxU5zhfNUuI0IuubGDEwgYe/2b3hmf4IAlNUZ2qGhWvkFkUoypdlkLJtNKXVvSPMJ2psVp6FZrilFQve6kIxvWGxDSSDrEgaU4no1F4FdVMAsgLHJ6h05S+wZ3h4gncLLQ1Z8DyODgR4Xt82oamWMShbFCFRZLKjqNq7qRx6Nin9NHEOkSvIR403Rtm4NEx7bQYReGo0tQQ1yTsNUZr4GsRu0KMqBzori4ijFffwEGzGpV4VlQrtLwjqyLFwS6nyusdMOvQqq3Bs3cVXlDp0RUvVQMRWenDLAzHGTUtoCWgMwvwzGpTh8Bsb+5kyqUGwIuYraEtYVkavmawBfWhjSJIMAQXvnAA8XwBCXE0lKhcEP+DGdQgnyTYQQ8GwAJsTPd65OACMaHmN6jiChkf49pQxVeW9VrocFo1rHX1qA0yTgcJ2giEl4ySOljYUAmLoSxMb/ufiYGSAWhknfqK+NuVZCkUHumEABaihhncwwH6pUYdlXaWIURlJ3MgSTZ22I1vwEAcyijHObIRhCFAp8T5CgrsPISvr6G3DaIFkH5Cq8e7TrS0cwkIHhC5T0DYZK7Ou8kA4WYKB2AEAW3MqYHVO9n1BMdNnnDwiA3jTMFi9gh4oRpDmmao8wSiDzE4T9VCClqqpYUTRxDuW7wzlzGvw82Q40WAZ0lg3OaYDYFtQTl244ZBz8MG6myddVVQjS7/pAMPQFCBGBbgkxlggT6EOKXbRFC5u5yFOUmtcnontmF/EEbTvu0ynvJFuh7glyuMgFABmrHGnJihG5W2lANaTFulcYcHli1QeKgxHrqkztdjPhisO/S5Px+4oIC8KoV5WFWjXHUebTopc1PQgk/fpBpX+IIrlupMIxDilm6DwcUeyw5oq5TUwdJWVt1pkuXg87de/o4iDOCjtyDkObL+HArg4lwYWKHFi6LZebRDJDNUDUlXWhI7BJiWbWgnN0ejmEwXitD9xkEXQCBqyEPqArJCdkaSNVOQU35RzhYVBVOOA4yZUACSjxqtlTGpyzEK854DvePIknfQMyr0oiPd/8orTzrTW+nSplMlom7g+NKVRfReAbWjNJdwQ6jujJnTwevJCHRlevOTVTtCRAhsyan0QfBclKzrlBXrG9iqdJZi01EoYk0DGG0OvyfBAQYLjgqkShWwNjLAFroORMTuGrDHwfFOv+mp/KbDVU+nAf3YJ+R3PgUmEMDS5Xi83JOh2FZdnQ4w60KIxfYRf9TKEACfTApesOUhIYKwDYmHVhUviuqW/qOd/ym8JSbtUX2IJE3YvOzWbrLEgedPPEicJRoRvkgAP0Nr0I4YgrG8dQM2q8+oZdbGDwkacMERNzTFDgFd9f19z+IUFaK7veUCJH1kx3gYgy6X8flO3IC9ef9X+9necwjg981MKKyW5dSS5dSeMx2CAzaOk8WSLYzd0UXEGHDNh9BCI2DeozXK5bhI+/TDRMHHEchOq/nen5wUmsGD+UQFjFCWgphCQEDCmKGCDdIWcyiA+SzfV7TW8Q1d3nGQV/zJtaGPqKUTN0jSoIDfuxWID27EdVzRNohREa2gbQTC+qxavBwFDQqADuIF/lwMmr2aKNREGFbOsk2e+5FK81QB2uXC5hXIxRxRFzyZJsxQ2VgSlMVHvNBEWb0IuhCIKczMeznBDJXTl3hJ9gyf6ulc2AFCI7TckqXHAdTfEpKe/hXWfRgRklEBa0XDa80fAt1euuVBk7lJIYL/iyJOkUi5BQJQ0wnFRiuiAB8Zn8chH1McDh0KBWSw3axZBE+EVIUsoacBHgsyQTikDCcQRx5coWvUmk/oIB6YQTV2YiNCEgYOj7ZMYk9gYuv0mDlgokepxQCEXjVQQe4JloZ4YqVdWoyoWhZ2gsCB0qrtkxe5CTy6AjauUjQ6Qy3NRiAVBjZeoBB6SvMUCCrOmPOtQZ/cn8H0Sbvs0ljdontNjf09Y3fpDtoUWuFIU5vEDyNymSY+Hd5NzC1eGN/5nQAlw/+4U+gZTrjgRxEtXLnlxXJswQDK3O+BxD2h4skBlKR4ZAXSzEDRE9y0SZMBQ4aI5EHqItBFxelRxQM8/2IkkovLidxzOURTFE0lHtTP9VzNQR0kvh9O9SRVgBjP+RzZlWXTpR6svCXUieVc2mVcVoVdMl1d6uUd2B2ZUCWOnSUy6EnxRQaiBKZDSJ21FGZCuWW1jMNdWMl8wUG3EUZvnMyn0N3UGWZkoWRECF4baMfJnJQ58dFo7sfGSB6p2F1oQuVJrhSgDAlRMFVjoQ8PrNJCTsRfXkViciNKUYWSHYwS8hhxDgo1IYRvKuZVtordCWcbRtuohAkCnAAkjIj5xU0B9MY4tWMGeZgo/M+UJCOKMMgQNMLJoM35yU2WXE4LaFmqZdVrSQ4C6kyGtI0aTCd0Aqdf8szMnI/Y0f/K6GmdafEbDbhTlyTNyWmgbnbaGAhA98GdJbHDVeVN9c3HfKJfAlQBD+zWLwSDLKRCfwqTfpYaqSRE1cChKq0hIlTPkRUIY3mn0ZxPDjJIMGZBGJiPEa4Q88RPbcKjNbSoi1BhJvkXUiwXKd0J9EDBiULOWQ0mHNTYs/0h4RhoOQhoYRGo1tGHQAShGRkJGtLVCyrKOMpG8CypgKTgCbrP+KiAES6YU0CFVFhFlDoeX/qHYwBFDvmbIg6KKmRhcTxBMu6RggYXM1rbdjHbi3oVgfAeyLAikz0RjNBX6fwO78xQ++HlG8RKnxmA2HndIRLnbLightxeYtALnp7EBSn/3otkCZFaar6oxR1iEotkmWLcn6SKFAR1KoHZqX+MYydopzmA27hoQW2e3DFoQVnJwTWG0cWgWBJmpqKCDD8SqYtMI/kYkT7i6j86SAgtKdfk4hAWgxp5CGWt5pWyG4oYqpbe4770GEE2EatK6KDGKycY46wqBWEMYneSq5S+JuWxJoiKD048JYJMg0dFKqqCJ6bIycK2hvhEqxIhbHt61U1mkrrhqm4Ga6VOiMCq3GfaQXlp33CKSRuga7fJZFAdqEm+TWwsk9FMgbwq46Cy04NKpD5lCJ8NUaZsQXuIbJ0+JrAsJk6JHDJUUnSKa18GXa8iy0gtrQhqTtoBrNUp/23RMW3VLi1WYm3MBe3W5tyTei1NXW3MKSdcai2v9BTpnUnZ1l2mPgxBReVFvR3XeSBleq3b/mscHCLzPCxEdBXpBZHHsK2v4K3gJgzcwiZGdaro9YGPzM5mzmXhkmgbzGKtOS1EIFbcBa7pSQZvdk1g5s9v+sd0VqdQVNBkatl2mq5o6pdzgMx9FsZ53eXZusHMUME9cBxZYCIJmAHdnBY89OTmJtRVyQIDvN0i5KfvJmWSwC43zFM5wAJVlcDiNCB26kx4TmZ9embcmgmTwo97iCGLnsX2wOisCcUAPq6Zul5fSu72FoNX8EYfKKSYFkQdIgT25AFXkqGiVgUZkf+DA8yR93IIGImERqjvwTQD9M6SqNACbYbvGebgiu6v+06tp6Cqn5rEIS6iUGZhIDKofGldX6xm0rXvxybHAMha7vbXAX0ELxAZgWpP+QZVA7MGpJ0ZqtYGoBJDTw1q4J1ZtcHCAASQbniCK7YHXxix/Zlw4nrKrwKDChgkghSrVcHoPASVCHcm0JVwuNJBA6hB7FguZtlfTT6SENwDt/Ivf81XHHlOin0ZrWxILFkNUWiEE+Ai53QqiOzQUpSIijIaBF8juKExBbuhdAqsVxBs4RgsyGiwfz2uHY/s7IKtG4AUYvRtOtXkOc0BuCHlEanC44qTOxXA3BQOObnXFmD/VcJ56wr5AqJsQadaSaPc2FMuZUiCpCMgbgVHy9CGbadM8qmIAcjVgVXilOcycSFHy+X2MkJm5a2A1OAWlTHrMjIvc9b+cjW/XNdi80ttsZNus9hq8ze35TV7nuLeHDiLrjijJe1OKTI44qe8M8vap2KhXIGFszqHJTsbhzRH3SPSXSbG2z3j87p0M8ycwlUtzVCohqSext74MNPkJ3B1m+bJUCXYDYOMCNbIHCfM1rIZp0GN7UudQ/bdrT6vQZn+Au18hzMytEr84mSojveGTz+gWTyfRheg0e8AGAJJWW2NMzMX1Uhvc0Ff2aCCBQMt9DtribVmgpn5mQrGok3v/4wNgVAehgZzmrRZupxQYzNRm9oqu9GEyCml7lto8UStLPULZg+EOGOw2udzION3QuFPcy9NTcOlBmnYejVS7dEx5YKeHMBY34ni+TXOgGgK6RM3cQIiK6M0pesLuNtHE7RArwtXV/NeV+1U/pOyZnM6z5RlLzNmKy1ZttdMhfRKgXYvi/ZAI9Rps3ZrZ/Vrg+wxy7Y9kzOy8HLLRMsI5y3S1rZpxzZVPJGx2kFuQ24zRnKrnJDJ8LZjevZv5/NtR0bzKHMx5Pa3YLV/eAW4NvfkSgR0U1lwR0TzrBJ2rtY0QYH2YIkpyC6XpefxAnEE2Se1uYaVRB/2UQTOEIKblP+RC6JmJPmChc4fF1MzeAe0dNPBgp60IizXir5GfqG3Jt7OjTXS+3CgYCnwSXSrkurBipYgppCgqG3Z7ckBbDD38XSpx1C2gdeUeDceA62DBrNihKMELWJQhXsTEyFBhicpJIcGn1q1rB6DC/FRSMGxhA5S57k2i7v4U1Xe9yAANlJr3PBNRhCk1wVlGk9U84RIj2epsPodMX4J101FVIzmm5JUCin5ijP5flLtkx+rfQyGxVoOlZzGy2I5Pr5oo3SBK8s3x6YyzXTCzSqPMjgAOGEbCQCfmmt1XTfdc/7UA3Itgp9K0RZddzt6id5BbKEASTuEd+RmcTdpGhUClFz/A6KrHo440Zw382yHDNQGne6Zy3Prjna2QE9Xxpupiq8dLq7g51BExVkI8YCjXpO3ua7oT4C4gWs6rwhOwxY0wnEpl1iUQKfDGFWFVBFYwUldF/opWlZwV3IuAYxpu0zgwks0LHsf8fTUGmm5eqsfO6WrePhVhMkSVfg0wRBAgoXdxYbRgp/oQwy8z0G0AzS5wIklRDhE5v0d6QJE2joUfHugxCqNBIXjAY4ExmI8Brwnbby/O9JmBWeT0pe1QFzow7KZmYZWV+V0g6yNYR6woTqxkXWxhVvABYPMxZwlG8wzFUqIRk9heTSoj7vTo6ystsdzfAUre3yEgpStkhYE/1wg3EOlDYnB+Bo2FIUqPEDDxQuMPQmjgQd0kQcDmAfGxcvEN2tyU3mDNIVMgmVMfTzSj1DXirJBXI6OxAhmvR0hLAcYNAUYDNkq3C55+t3DfanEKUnqqIL5fn3c1fmcqNUMJYkqMlDSW77czz2tY/7lvzpee/7ng37oi/7ok37pm/7po37qq/6Sbz7ct35e1nY3v753v77sg/TsW4vtm23sx2atQC6INR60XbfdRm12EzLuL/FA54pLtgGzE95MHh6qk+JXMZ5DrObwl1a9oHqBIz+Bq/Pyl+NxSDqJ4wA7cnZxM9b0D4inp1VTGT+WFvf7H3/36764DAsQZKK64P9f1PsUCARFECjkAQANGQhpMQDGwQ5GYKT6+6RzPQgEEazDQsVyCUgFBmBJIuwYtEDjyWKMRE4hMmDcDRKBBOJGQuzW7HagDY/L5/S6/Y7Px9/6vv8PWMfXR+SSIiC1s3Bw5QUQoKbTAqBQYHAzIJCQQ+DygKKSKHSTw4aT0gAqFGToE/AgYAnQyZDg5NDA4IW4IwAKoBuzVuDwmBl20AqQ4IKQsMAbOBhIXW19LYitvX09fYdwcBB5mNgrldBjvLMrOqCgkNKpYlgQOXpqWlqfssrHQMACwbt4AoiwqFeA3A4DK8QhSJhigQkS8IRMpKiDFD8D0QB54wYypEhTI0v/miSJh8oBYeZSDCCwYJGLBlceBDgiKUY0IbFiFhCw4CaqK8E0simQjiawfikUoAiKoOeCn7WcpNDlpEG5Xk0cETlyoOIxnGuYPXnW8c/Hk2zb6lnrNi41uHEYWF3DAsePADBlVBnHT2e7RUwECLhydQQNG3m3KigGbMSIAUFckhmBgHCCn1gwTjywFQqkzgGoMBH7ZbSOMWXUpPVDV67s2bFn2852m85UcOnyGNg0BV9uubWHG+dW/Pjx5LSjBHJgJAgJZcpPMq+OHXb27ZK4e/+OG7z4t+OVXy+Pnnb69XLOs0c+XDrLa6/LGxhBvZr799v38+/WRzJxsIKXMA+t/yEgN/URJFtlcziwFTb+/WcehcTlIV1+V5FBnVcQ6ZDAfNgseJuDcjSgoX4W8jfhimr1IQ8bvz3UoYEfUsLEXsUgskQpAAywhRoXqQHkdLEoRtYsLoCRxo9bGNYJDiuAsUAQIyQwZTF7wXMklVvcyJoZBgkHoIvrtWgmeXrEaJAlnHG2jo0FqkBUiLGIaAYADySwg1PLtBKLAQvkqYM8k8Typw53PoGMAEHEUIAURKgAz28MBDooAiaC2MwzMW6DZpoXilqSf5/qMOZ0cR7yS2AA7DNLVBGiwQJHZIhg1BOJwMqgFw/lGs1FJTgoT2VbpBFNPZvKgA8Op0pIanmhRv9Lh6kpvkAdaAAsAs+qSgVTH6HM9uBAQmYp9CpghsZw4Lm6skoWsS5U1kC36Cor1A5mabLAs2VS+920AO+B4UFxwKmDaXwlqY6O765RpAizMJEQay0kq+6S7FZ8K5Q6TAmJvD++sRcOGBMGJhl5+muNwAOL5PLLeMlMs5o1VxfzzTnfbOHOPM/1s4pBDz0z0bn5LDPSRku79G1KD/y0HkC2JIiIsFktHolwRN10tV3bbEeqOp3AcB4KKMPLQO1h/RbbtrFMtR1cf00w3Xe4d2DCpQFwAGR9DOrju2rv4TYejigHt6IRzjG33Sg57jUeYyoBSlqxnFBFDxHzgUAiokn/MfjWf+HYpANZbOlXDWKorAYBVdi7LUBlvOoCKc5MFwQNTXS2u2iiaRokaYu3B3lbjYs6IRGXen5joDe4oMA5xTh4QA/BCA67G0rwqYOfr3xcqS1aucopAM70K0UQPgZBFmekEOB3EFnlYgsAuFzP4DJq7Hm91m4Uz5bjpalFPKlcaNqhK41UphYpyFvasmeKGKhPE0x4wggUMJW8PMQeLDGKs2pHJtOZxX04GAANCMAAB8UiVQjZgTxolQaI+O9xAByJAM3kngao4XxY4ZvfHsaORC3BfpDp4fhCN75VlesG5LqRGeq1g28dToieAmHgruIsLgmnXtRTQFX0xhL4/6VAXEYcXt1qaEM0ntEOUCAUFMKgOFfxok1vqF9TTgC6vIxBRAeJgewKUIBBka1kBtACk+YTptZZcTUsgId0aGCAP6awCDkQjRZJwACDAK+CnzHj1tSYRlDSMC6x+MQdHuDJ8SwrLjeEXCtX9MrOhChoq3RLLOl2y//kUpQw4yVIdvkeYPoSVMMkZjEfYZ3CVec+vSGVMI32zPS4J3Frq2U3KMOHWq4LDmMom4uiOTRwMs0kUxSJNSMYB3FQS5w/Y6d4prmk0ZkOk9F7gRqY0iU4pmCepUFdPhegsEZEDAY42Bv7OjGkZzBqn4ghQCrPdExoHROej1BCQr7XlF3dE/+bFhSUuB7RGyhaClNm8EWcHFQZAsADittMl0vNlwiHDjCi/xomRX2VkMthsJ4uxadGuVKCDAYEYwwBw0ZR+oYxaKSliHjAhzq3Tpq2LKI33Zi+osKxo74BY214Iuy4eoiLYvMIDgJkTJeUjkElyH4Nfag0pSq0YlbVfIG8lRHuA4Y8+dSeOhAklQiJsd8ZA2UOIoIw5DGRHDhAoSlQ5yzcih536oyqdvtUN6MKV2lQ9ms2wQkzASbZmoXWO6PNbORMq52JopY9pX1Za7PzWnSF5Jxvu1ZqVws2XzZOdlbwwwxXVbCHucWEJFgDNfsQW8zK1SQqlQE6+vDbQNB2JDf/gKCStJHcaGV3OcyFRw+h0DsWSIGEHMljkzpBgBv1gwb146cWrFgZXrgOI71gQia5Z9IpRUcIkFCoSXUAITjMtwQjG8JtcWu4zVYjeMYlgVm+eL/v8YK8afGT667YDz9WpDfkja8UZKq+hLW3AZnSny/A4qhJuJRXs7Br4EBcQhUfGMFyU7BIVLqIYrDQgeO1Ii8oKDF/MYUSXLrgVOC71Q8vsoF5ySkBnEo6ipioqTeaR2Nh98IYa5bGCVZtSZo7oy9iMSsf1mJ5mWi/hAiZo0S+anN75OHr5krMruDMiRnZ1wSsFV4+dCGSt8zlGnt5JM0tsCVJF6mRMam8ExOB/5rzM+R3+HW/i45zlgN3aEowFmSamsZiyzalvhTqzx4J9N1sPBwoDuy4pTK1oJc7HNkd4Iqi6qzTXB0em+KatLtmHKp7zV1gf3LQwg52sYsG62MbZ7vI+7Wy1fPs7hA72tCmNrOHk5dsa3vb3O62t78N7nCLe9zkLre5z51tavND3cFk99Ku7W54u3uq845svcN573Hme7L7Bo+8+41cgAdM4DT797EjIIF1A0ACESB4mhCucIY7PDcUCMAEIBAACEwgABSYuIsqfvGMb7zjHrdNBbJdgZK76OR5SbnKZyOBbCf85RSKeV5mTnO5bJwEE8i5hXZucZ/LBuMkgIDQ//9D9IwfXS4WCIAFlv6fpj8d6m65QAAuQPX3WB3rWWdLBALQ8K6n5+thF7tJMGD29aA97WxvO4vQDfe4y33udK+73e+O97zrfe98Tzdr3Q54iUI08IQH9FsLj/iA/z3xjD/14hsPeeI9vhoAgSwcootO2LKZcIHAPJ7ZWFzjaiyAyiyJ57Hdbo+QwAB7SpJoYHAIuwLm9DnBw3TpcHtjTLecesC8F3K/Ld5fV/hbK/3aTEIiy1l+1G1gdW71rRbBrAFRs7jCouz31eUD1w7AH1Byhsx5QPhegszRhYBHn0zkm5H2d3B+HuQ9rXs0KayNdcFHp5++IN3ACewDbxfmM2D/lVIFxfAlYvAkiWRBSPIljwIJb/R/lYE6JYM1VlIGWWI+jfQuD2EDr9MnAcEk9RMxgLEFCoCA2yQ7MIELvYAC61UGTvA5azAlfMIkozEks8CBqTETZBNQGdFIY8IlkgID8sWBEuhnj/AXY6IprGN49iYN0ldfhYEJnZF9+qMnfNJc9QJhAuVC6SMldbJ55TNGnQINlpApSOUCPVRPTCFS4oNAbPAoryIp0/AViAAOObCGd6EOb9hcebInYsAHZnE+6yIVydCH9YQiuucFKqULPWA5ssAPFtUnKABjtsIJhtEo/4V/azCHBFCH7zKJqUA+vQKJMQKIjDVj0Hc1wkV//0uxJ+MQOogAQyW0CTjAQurAfKQAK5y4LEbhQYyWLkjVQBAxNUxxLJAAK8InMpUBDrVCQelQjIDxe3zwDrG4PiTTLJGkMWojABj0CvDjDA8ojQrAY30COzh1FhV0aWqDUHmhAEXlWOiyjKvXjApxaccIgKN3IJe2EaU2ean4GtQXDIsVCaqmEPdnVsBgR6EoZ124FGNVFq2wL2ihUewzMmMWCohIKVFEFF6QRC7BB8XyBsSgJyYjDhxpXSBVkW12fx4ZhmfRLxojFZzRAGZQC9wTaV60Nx3ZUbX3K99TLgvJEYF0ZHc2fc0DCiJpExxRktJ3aVJ0j+qQj5ARkd7keP+DpxbyGCGioWJA9o7vMlBMJgyHNkWX5jAoszq4o4QnoztTdgLgmDqrZ0iLsQyI9JHzslVMYDJxeAZVQCYTMSlt9pWfV4Kjd4JHwC980y03iWgRIjsyaFV/9GjMIihVIJNDFRBTQAZng5eMRgSyApSGNBlFaI6ahID8aJX3hkp0Q5DYsBtyoQu0FkCpF3ngIWuwqXp8MVxJYBvwN5u9OUqo6JuzyZshwX6/ZHwQQwLHKV27ZVsKeRybMl3yUQfFaQfuBx/9GAinQnsxYp3F55x1sGfc1CLAeHzVqSHauTjERxtfOF3hKQfUWQfdOQfdh0zYOSLad10tIwzqGQezNJ//45lNtcGf5hk3tYcd0Fkb/jmd+IkH8il4h5cRVXAFhZk7LdgvDnZdLxiCSpJeQ4KE8uCARjh/itKWF3EDo7Oh6PUhE1EPGLgXDVCAFMpfiIChOrCAH+gEX8IAJqooWxAOJNADICpeNkgRtFKOKMpgHjkE/reDM0gkShiAwCChiKg7k/SWsMOiDsOA4/BPPAU/sUAGYaBfVcJfUTGknXA+CxWDvNMFI3gCFemD8ZCesokK5TCIKaZhFEkQ/XMO+2OFsxaJ+UkLe5OGkKg3TpCG+wmJfPinGDYfX9GRKiSUyUAgeuqHSjoLsCOS5eQ8k1BPg8qIH8aFvrgO20OFfchI/2c4YphYUWeRKIE4qqzaD/NDL+GDhxzphQTCFR51BnphMkL5E3dGqZOwiJ7oAvtQD4GyIbfQCNBjCZiwKV/xWL85Ht7AK9pIguFoP2XgAmgqQwRAjTECZJGpJHkzjFaFKsIoVq7Sk3mBjegUjzjAKw6CrSYiQspAnpJ2EahBNUHkrfToY+lJftT4eSzkjhs1Mr1Ilg2hVWFlLBq0KrnYaWzAVZ3gAD8YD+/AjoX1rRn6ZAkxOLUYRBgZr7ZZn6d5kWHlEynWFPbymoNKZlR4iz6pZpABsxdpjoeKs+lgjh+1Zq9SDEkZqUIRkywbHNVIVuEorWGBkv3KlAJQRkDJqv+u8pMrmZJ01qPqULXb85KSmbVDFha16p1OuUpcBST1wwszQpRXm5NKti16ZlGlgLUjS4xBewoyhWwQ6gNTKqMtKx0Ehlh45CToaAiQeYGQIKRg8H90NX1tSTpReCBf+bPgpRcSapZ9q2gE1ldrGY57UQDwkFhxpA7yBT1M4LakUAuayw9MIEEF+HmkoZlN0kc/AqU+dpn9cAIGAIF8GTheoKUfAVbaQhqIwWkmwqJuaz+M1ZiwO7rtEF+bOa15y4SNt5qspJzKMShhyaDV66BLCJyAV5u7eb3HAR2iG5+5uwO2Zjx0GpzCyb7tC3nDCb/ua5/zi3jya7+Nh7/5m3j/8Nd3/wvAASzAA0zABWzAfRdtBkd1CvxsDLx0DnxsECx0EixsFJxzFtxrGPxyGoxrHFxyHoxgEFefEse/ISHCfEDCJbwDIIdxGsdxKgwSLCxyLwzDO8ByLOByNbwNN0wCOazDCydzP7wNNscCOCfEQNdzQrwNSKzEOpB0RtfE2PDEUZwCUkfF2mDFV7x1V4wNW3zFZMfF1wDGXLx2YWwNZWzGaRxvB8zGbezGfuc0byzHc8zG3kt4zwTCaBQqeWw3eBycexy/qOebgKy/gtybhMx4fjzIduwH9AkHukCVdXCI1DDJcjO+BXqdt2YNCMoGz+VbiNF5oDwHTGu9IYHI/3cQFFWWkggTB/5CfX6goHTSByHSQ9Vyyeb7S4aMyhKDnJd6tH9Qya6qB4foLm0ADm3wW8DXUgNqmqdIB74QyylJoDAoynkAydRwzXdzy7KVy0fTewcQzZzcC9wDy830B548B0iBzG7lyI7AzC/SzJEhY0exjd2yOa/SAn85EPwkWCBSBc2gm6LBGM5xzH31CjZxQZdQBedgPW9wzOV7AIqhDERYmDvof1wRphIRUz8Ez5qcMPhxMPXsEscyuKH3MQVABlJAK/mnKl9yCfnSWA6QynwxNsnZAFLJGAvQWeVSBj90AzjhXj2IgTzSZAaNh+iwjqvnpMbU0ajAAt7EPv+XZRbyos8bxnzBoQSeZgS8t9M/1Fm+wABQEWCu4IIo4ADF0DePUAw/+THtcKeYmIVcsbKkkCvxLBveADJQfRNSbZeJsiwJIAX4M5IywQZB8QCmZNAPMAZqEBZBwRKcAcmmVL4OpdPCMTX80BuvMYewt0rJcB8IwEDLbKgPqngf89RtICy9mgNUra061bXpi19GsK9YYGcFuGfle4hBYRc00ACsxz03zTdA8Qrmx1Y7YI/YerC1KLrNZbEn+XyjYtok4E2prUAFtdrToNtLMYYV9BABoGO8m4I68NWJICBL8BPZbVIpmNazhKoj3aNBFQ0lGw2rhAsK4FSHMXz7ia7/pJ1bhqQhg5IOJrUvdak+MwA7ZiBGO5CC7+Ung9IKzuAMnEBie6MD690D7U075esMD6DbXw0Ke+aURdujWBtHM+IkCcnItrQG/t0GAM4qQlRHWQ3b28IIEV59PFismhDcCo4CwJ3dDYQON0EFaC3cD3DN4e0KDFNSR2m3vmipG5IQM9mtaMWuqgw0di0HzoDjBkEDDAIQeoZBdrUAmlThAX0CpcGioM0EzDAGZWHkQoELtEJiGTQCVcIn+VUMP54Yh9RoMCFYmXYILADKwhtXuyk55Lx/XO7QZ67ggr4UIsAMkyNUjPAIeAjcz1WITKAGKzACPVAakPxf4anOkwZQ/5lJub5olvriCXdbugW13zVV2thQzDSVvbB+12pU0M2G5YBgAoCaWeVr69BdQ6Q8U7sOeIp8yCnudshOv02dJt0LWrpcHudKB5y4fdcA7bjcS8ZOHNdLIqw21p2hTxEha2R1GXhoQ9vM7HWwF4BhPrfi7m/p7r4zJ4zbFOgXB7+RJO+cB/Lwl4wjIvD5fsoOHt/enM6xFE6Q1gsBE0eWKMBOTuou7XSgFOq7T65Bzh9TEzCdvhzvIREBHAO6jfWODd3JqQzqzF12BzUYpWBKJVvqgEHQA0zbD1digT5opClaEP7VKujyX1qTDNe8LEut8+n1ol9gBF1aK8/NSnngyf/Ch+FjxLNY88rkkzdQNViUDjL0EAMSSCuyvdFYsAZffwRbbxCUoFEBxaNhldGc4eLBrvJmI4kbeSnAmmJnSKhSsCdJlGFweIE7sIlj5KfXhazxHg2HnxBJalJI1bumyqg2aId2eolkqFcS782Gs5/x/lltYouqwYPl9PF8w7OfsD2VqCegwPcd9Ap0fQpD1AZMpKwgifb2JKsBb/cHkjdwX5VsdCvk2oAxla3B6N44ghNDJvvyrdLZ9q5Uts4vrordEwZC7w3RGK704IrsyFX8Tq1NjwdPLyK1EO/LMPVt8JrAZVIMxA961rIMMsn2+A+X2dx1wVsC0S2yz1P1cLD/trjcYW5CIIAAI1maJwoEKXuurWkED+AUACEAT2AIBMCQQAxejAAD0AA+CgSgalAc5QDTgmPXExxGw1J1kTjoTr/RMXnIlgwHRSmhc3RLgUHt9iVVlVAA1wLJGUCByAwMy0siY2PKYmNDg5ZggY5AQRKKJKUMHgEej+bIAdDCWw2bCkIpYMHCguVCgKDS5NGAQtesyEBBgiaPQYkuAC8mrKXVCqbVnqsKTcmZkAhXgqMjZDbJdiJBQEDBDXj4ZXjA5NSIQPgBQxFDLNzdetVUu3gPQ0KAgm84cmUcJKhlB92wfAcMjkCATpwzcaNGoCuAByDEPm7CTWqADgEhQwAU/4Qbxs0bt5SPuG0MIKKQjgIPX5JoKcITIHRlSDA4EI6AIGDdBpxa6FOcAAGT0Mj0KaWfzJetRjiAU2IAVJenAiRQNsVA0yH5XI4sOQjd0lk7Va5kS9EtlbWE4NI90aduozt493bjCxel38AP6rSIxUpaIzF4SC3OJgDbXqwM9wLWRvcuoD+B2fKYvNmE3s9/RZ8kbVrRT5V04MoIsJbums+V856ubft27dm4dePu7fs37dHAhxMv3te4CuTKl/fmDcM5c0WNo+N4PRz6aezUt1OeTlo7CvCfF5RbaEKMO5MuvGfDHNg9H+sp57YQL1slmbMBzJfoGc4qVhLdts5p5P+5M1kRqT3CniPwteWWfYEZAFQs8pGiCmgMNuLgXhxy6JhmiigHXoJlpAFAbCUgkMWJctRA2GkEmjZhMhYKgViGbn0IGl0kyuSSDEkUsUA+mazihF5DopAfCoa1cdQdre23gAJQEOAAAv24RoJD4RDRzzPLFEHEjyL8aORYDBBwlFUNfXRmEi4V8M+PK7SkgJRtPlicfX1wwU6IJMzCwBGCyFiET2gGFCcCc2IkwJ2uNBVLQFeVGeQyRC56JDgX0bKkhUeoFwSUA0i5kDJiPJClOVx+FGCYx0HIzRcPYEMAHA0owE8SDkySzggKwCEsCn8W4mWwAYS4BEWNyfCADAb/RHslCn24mKVBRZRRK2QjYIELH0AUMap7WKiwVAJZTKFrEMDQJyJyfZZBCCZSqkftOuOSEI8tvNbwK7o7sSsEA/WKQYQ33OKQ665C+XpusMPqOUgX9nq7ZQnMRlHTDI0C4DG1dm2rA7Yu9JiNlCVhFW2XlYa2cg8n6OJZxnqKFIWaH1VXlRU+ETBRFdFSpN46KSNB0n8exxdEzEtTiQ49eAh9xUzv7kmcvOzUYfUpVhW6zFUvYNIyRHoJffFHISEcw0M9wGwA2Te8nMDZxPDX5M3evnRHzl4qdkAvPgOtw9lN23FyNrGOA4S/Q/FxwFI1oYICAktBnvEtdxTDixW//0zELh9suPhYtos845Agb4AbF9PkZoE6ilF7cY4Sehr73Igq9XFiivuG6eJq+76gulCOA+DiCKADqreScdDkrRMANN7s45GP4MbEJChAOPLJZ57LLmRdY4LyOIh+SUEmC+cIRjd8HNpYso/Ag3dxm+DffqMy0FQ9WUll5aZc5RJYPY9A7WvJnHISDjURznDvc8lREhiaLsmEVAjhhz9wFy9uJAgiCrxbsqAWESMJLz0KzODczNGSLUDBEFtx3wja56bFxG9j8wuNACuloh9ZT3r8e4o+RKAWKgTQTQME0/NkxZYIscVqplEMd+YDQ5Uw0S9V9IuMojiIQJlGMny54v8VUZYAHNUmeFpMRD4SoKHgGCeMkXGjbW7Um97hBYxnvCMeebTBPPKxj3bsIyC3A0fEBbKQgiSkIRN5ndzZJoumCZkis4PISFLSNoNcX4wA48SUhAaKlRTNH/HiyE+ypXhvxCTWBqRJLnKyMTwj5WZC6YhZTDGGL1AGDHbEF1uxo1uR6CEjjgAIX8JllJbZY4N+UIBItQwOLWkAorgyijw1MzPtMIBHWlUkBiAtZrzEASthyclJMuIa3jFmCnS5l4f15nannBUyN3SAYQzMlKjTmJgWNo0QoQ4TeHjMMHLgr4fhUAZUCKc4syFLH2IMBZYgVufQcSwBOCRiNdCJzrj/VCb8zWEcSNhPOlryT4yGYzBZcEB6aKms6cziATyQCZ5aAoQxSm8FCsjCGlQKihKgdIHPPNUCvsImhTIymWjzEisQkrd1QHR5H4OSD6AA0RzYr6CXTOhCs/mpEwzJiy6yB0VfQCxEsC5sLxEDyVZQCkHY6iU7dUAOSDgoY8ygXjDBiggmd0MivYMXcOVYEv50gAe0FK+xswNi8MmxB6zLmaZMxFWXyI0+lM9cwsAnU21XB8uykB2vqND0okGCbz4hoXXJKjpo1k0gxQysFR0JHDDhD/K8pgGqMJat5vovdjykATRFA2Q681syEIJJVOlCA3QwKP80wADftO2gOlNc/7nA1EloKMcAV1AnsrCRT5Mtwwp9EJAePDOz/enH9sYb1RFsBSknHJZZXlla06JynP2RiXxUpbXj0a4648Ke8yCZvD8gww0O+JoS2MAJEnTPWKsZHd1sS9eJxIam3/SWAFaTJZdiYzUS1q0JhoDPzWW3dlQsKh+tywJP0ve05GxBlgDbJZ+wDhxjUAB6ptQlmuwvHA5ob2wJ81v8LbNlLi2phGeMBwsTc4xf85WUGpAMfRCpI1lgcglyvJDy+k+oCDlmG/2ooBYIuMX1Lc1mumfmQEb2xGt+MzzjvBeSzBPObEaxnfMM2Rfruc9ttm+fVbJJMlsonm4ONKKTY2jRgP+jgVJAxzz1NRKE+oVJBprSPlPiIBw2Ap2Hlmx7Cn0aAjyP059UZyLA0lBFh7k2BJCJtOoRMwJAs2lVqk2JrkchXDo11OFZ420W+g1Rx0CNJ7g0CAkEUSEwxNTKEQKDekpCkbnlDH/VY6tHXSUCeEJf/rT1sg6kgKVQK5sL+UE75lvm6pzAuJKaUhHGdAKtnkMi3RSvgPThD3eADd0OBDSojVrOcLCHRhUKm/asIoCJOds4+WBQA5KwYGrTJbnqy3ZdymSXf7hG1gboWgfHDAjzkGFcogoEipJikdbVbWnTgJErPj4EbRVrmdUZ6K/wgHMV6EABy+w2M1bOZzDL8z//MDHGb+0AbHcr2yorX+EnfgKLcmBjm08yeqrGiBER5ODVWSejDVPAThLQ+1gSKRkX8Ge9H7RsVH9Gs7aVQPAOLkTSt9beQ+CQA56tdnt/2Hv22K09EGaGeYCZalgrsrGq/hMKsi68i89M5swxwGNKy5HZaeJOsFl0MANuFjJOIYDm7Zzsji3YDZqhsDUNw/K1pF5ZMhhDuk3D5pgxl0gMsfnlweftRHW1M+duOLtrBuVcSoCxjQ/5zj3W5QA2QwvX5ofa1yi0iLB+45uFD0p399OM6INW1Ai4X6dgZiYgkIQtXoi95ULhcECpHOxHgu0i4G8IMNqEymB/8lNu2hat/87TGN0PNEEQeMT4bZHgHc6ifQauJMujEQ24kU9GRU/ypI1mTEXYVIr8OZUhrIOxCYpPdEW9ZRDS4BsKZV8UbF8dDV066YAwjBwxGc+TBN4Q8UP9bRUn4ELo8VoaNF/yTIzPpU+Y3MX48J8JrIln7GBYpQ4ciIG7NQMC9h6e0ReL+cUDcB93CFsu6QR7rRpvGZ2KPEQtsUoAZIFS8MQP4YDUdVBsiZDkfJkMlIEM3cUQmUANtUHbqMdWiCACWQVBCMJYPM8ZSOECJpQZJVp4sGCnpY9oDBZ1eBFuoBq8YBwiJpoWcgMd2VkmnkZnSJ5v+F4l4tElhmKLgWL3kWKnvf9dwwXGKKIiVk0hIPEACUjbRIRdCuCPnoDD+akisFULsV1cwJmZp+WZKTJCMTJaOJCdxPXQKnIJiyBBCO3id/TiCnqiFjUjCgyjNlBjFB2jBsXIpUDjkFidnHRKpkijCYxd7G2BO9RiF/YKGWxDNAmFnOSi1B2JnpRdlEBaUN2BS4wFEFQBSJHF1mFbMLaYNuYFN2YhLKaZCPBSA+rKzgELbFUkOvrOqGzMidzdEZphkcmjXjQgRQ7CZ+XHSPZSQOmAVTHWlhwBDQyiSl6CHjwkMbWiL74aM2nJ6IGUouxHnByFCJAhpAyV0s1jEnRTL9SJBWUQRthU9JldJtybudH/zCEVol/g39sw3uy1nC3tkDvqhdL4wnlMznZBgnmZGkQtnC1apEAOQN+U2Me4D0wu3jLloQLK2ffVWT2piSrwiyRsJBBsSTNA0l4WZUjqSTF81QrspWJOmt6UgLnoBcq52zU2ZGAoTvRgX/Vk4yIgYXjQwIkolmGZwGsJj0WZmhKuZWpqTvhIX2gGpErigcfEihJ537Ad1QAJzjqMjfuIJVjewAAIDv0ZpkU9RkBMjXbNRGs5pd4E4Amuo+zdkTfWRyOdyQx94XPeEHtg1/3ZJd6xo08SQ965CjqO1Xbeo6m1lzL0TxApW0DAJl1GlAfVJsB9XxmUj+mtg+pAI7P8/2bN4OdQZNaz5AF/5YSJMRjtNANewQ4qIILy5dF0TqIWDRopqVgkBJ4xKiLFhVc5ZALdJUQ7xmeHMkB4EWdFdugNzJidQBUF2UlY3F8EwVcPaFUSdaNlLocclaLIbWH+HGR98kVCKkeQRlKEXo0r2plNusWQGseSJlKRJuKR+pmGRiklPSkwmhk2IlqSUimR3ugZIZtBtIN3ZGmgbSmXOqmXapHB4VKXjOlCEuOUnqkhWalBksbWYco4bko5JslWmUB+2Ar9gAZQVserIaKZyumdWaVfrB7DTORSEEtTvZyY4IQdyCQO1JmhximiAhKd3iVpYCXd9IBWOgNXjoR5rP8Wp/mnJJZij7SNq74qrMaqrM4qrdaqrd4qruaqru6qRCkqX2Am4zwWDq1JDz0fHrppXCagJW6qhDLrfeCadb4PDYkQDgVqGCre9Ziaqv7imnUqmjrrd+ARhYIrlJIrfZprNapp0qHrN6Krt4biu7LrF8krq9Fr5Nlrl8prvGYqvuYru+7rsvarIgGsHwmspiZCk66ZDxbTIBEsHzmslHIDLXGVnZDpqsLFNz0GN0ycIwiTxopSw9IrxOqZeJjTRdqnbaijbeweXSRss5LryMLpfXkhZC4cgNRJawzAaxFLT3UcsmiUl3BUHuAXSI2eTNjcWIyFSV1U/ugUS82ADXD/RRbI1PGApk3h1I/pw07NIjqQ6FE0Fz96WXT+KLjGLJJKYDjQTFcJoQ6swx3sLD0ghnvIG9KlFYoAxYskgRsMA3HJFTS2lF1ZgmHpFSU8wQIIw7UxTWB1wWAV1hcQLllNH9uwpIkRjI+WrcGiklap1kwgZ7PArSvMlntI2H7tQEFAY8pVoE4kHT/s1XAlBRS424OFAjYwl3NBBnQhgXTFLnXNVt685doMp21ibuYeZI/l12/9yei8gMcZ6/EgQJnhU4GtAYL9lpo1WB08GPpgUxaAGIoc2KeooyVo2Bjxkod1L+qGWOX8AYmtDYCSrZxGgAS8BQBIQAQU7+81Qoxl/2vluQPzRt2NadkC7Bga+hiQjRwabBUZAoGR8cAMJJk7LBkNXJgXPICxkEGUTZlMVFmCVa3pZpmWbNnXBkhUiO2/ER2zUkAATAAEBAAETEAAUAD+ojBenMgMxxK6VkDbVMANnyJdyAQW9jDcgasEtM38CnG7IrGNoisMh8MEKHESQzF1mC13tHA4QIAUv2wucSsDltqb8tHFpoCqFRoVc4cFBIAFZLEWE5ojQNuxlQdDNN31MCLsRYcbnwAttmC1AUHiGqmzXkAAXIAa+zEbD5yzrelayDEgMNwXryzBbcIy6nHFEVsZb0cEBMD9DvKVfsNQfd16tADTLQJEPV2pqP+hsiyA2imQ/0XK1xVk142Dcq1rHaOAypYdnKDdO3ztPrXdGjMrBmhyuW4I5bke/2lc6Zpm59WBxtxB6BEXYZTeD7YL6kHD6tUZMX9y5mFk7aUkZGZB7oEEzPEeJQNz8YIH+NWf+NXoWg4egixC+pXBzWiO+2HTfiDABpqd36Qz/vXB/mHzCTRKLSKec8YWARAgPR+gOEdxdvAqQze0Qz80RNPqnH6XFiTEAcTgLF8P4QpKSw7BLNRCDjLzZ/EaJoSW6ZlAEAbF8xDhRS9ItRCeK9QIgzbhGFBXpulShFayzCZqg3AhXVnHHebQfDaElphh5PSYU5gyUATie12dWcT/YQxZJx3SbFBn60PoYQhaQh9SRfowdRSOc3OQM3UWUhhB4mc4YnSYtW2E8Vjvhlj38hmF0Sa+2VyTRidSxie+NSFLp177Kg73dZ0+LGB7V1hnRyOLhstm4GHvGVnD2bhqaV7bIVpkJMJuA5kSEQTtxLgpXUqoYH0wCGVKMg1DKFl/8WMzQmJXpVvzlJFMyGJjHspCoX617BV94F/ztJmddmWTUk6HGBkR0KUanVCaMB5MZbxxF+vMgmzW5KOFYK90rTJEiwquCRgGKEgBA9LMSfRd2q3U2zuowKB6asGGGk4O1XDzZGCF6ECKQM96bXVr33UnAZyckLhoXFM65voB/5V1TmVjF3Y3ZOS1FERpjQskrYvjDcBk7qR1UFYWuIesfULczl8DGcB0i4sDPbg+6cXddWCfChQ03ppg1pJOb3Iu6eXpFTh/RtyHB6alRm5hWjeEdzO4nIHCNOaG08Sz7CbJcXF09Lbz4KFJ9EDQuI1uahf79d0o9YGtcOXjVaRs4Vh0uw0zwGfLNbl54rdIwJ8OUFVvyo1sivhE+xo+56aywIPYGEKXx+eTU0pGwXfEDLTS/AD+LSeWIwDwMtV44rYlpePTgQKE0Vbr5Odifo/yJflOjEGgWLmeDEEDXtN0T7iJXrmCPoOoeLjEBeaXBzZpi/n76op+7gp/YnqyMv1Y5WCoos/0az5vHCQocA5B+yrJg+p5bsgM1FA4ErHbtCzKFCC1XtCoI5XDS6BUjSq6ACeIT1D4lOP6hT/aaUrNi7IhuylEnGS6eAu2mHOorkMaiIbnbwpwiVp3xGw10rSCDLVoEDy7/7yQ3P0sp0b2YNOvrL8THqX2t672u9freG8GvffGvve3vb/7iGv6vc+6fwN8mA98we/5wAd8tSO8JCU8YDP8uTp8uEJ8X0s8vFM8wf/7YGM8vmt8xe9GRI88yZe8yb/qnJ68yq88y7e8Q4M8zMe8zM88zde8zd88zue8zu88z/e8z/880Ae90A890Re90R890if9HYUAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Proposed algorithm for management of diabetes and hyperglycemia in the noncritical care setting.",
"    <div class=\"footnotes\">",
"     NPO: nil per os (nothing by mouth).",
"     <br>",
"      * Adjusted based on current degree of hyperglycemia; consider modest (20-25 percent) dose reduction if tightly controlled on admission, to be conservative.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Inzucchi SE. Diabetes facts and guidelines. Yale Diabetes Center, 2011. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24369=[""].join("\n");
var outline_f23_51_24369=null;
var title_f23_51_24370="Congenital cutaneous candidiasis";
var content_f23_51_24370=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital cutaneous candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Kaufman DA. Neonatal candidiasis: Clinical manifestations, management, and prevention strategies. J Pediatr 2010; 156:S55. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24370=[""].join("\n");
var outline_f23_51_24370=null;
var title_f23_51_24371="EUS FNA esophageal TB";
var content_f23_51_24371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 47-year-old woman with a remotely positive PPD presented with several months of odynophagia. Panel A: Endoscopy demonstrated an ulcerated area in the proximal esophagus, which on biopsy showed acute and chronic inflammation. Panel B: Endoscopic ultrasonography (EUS) revealed an inhomogenous periesophageal lymph node with a fistula tract to the esophagus. Panel C: Cytology obtained from EUS fine needle aspiration showed multinucleated giant cells with noncaseating granulomatous inflammation. Acid-fast and fungal stains were negative, as were serum fungal titers. Antituberculosis therapy was recommended.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Norton ID, Wiersema MJ. Endoscopic ultrasound- guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography. Gress F, Bhattacharya I (Eds), Blackwell Science, Malden, MA 2001. p.136. Reprinted with permission of Blackwell Science, Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24371=[""].join("\n");
var outline_f23_51_24371=null;
var title_f23_51_24372="Transabdominal CVS PI";
var content_f23_51_24372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Technique for transabdominal chorionic villus sampling (CVS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 494px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the transabdominal CVS technique, the physician guides a needle from the patient's abdomen into the placenta under ultrasound guidance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24372=[""].join("\n");
var outline_f23_51_24372=null;
var title_f23_51_24373="Hydrochlorothiazide and triamterene: Patient drug information";
var content_f23_51_24373=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrochlorothiazide and triamterene: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/41/34454?source=see_link\">",
"     see \"Hydrochlorothiazide and triamterene: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dyazide&reg;;",
"     </li>",
"     <li>",
"      Maxzide&reg;;",
"     </li>",
"     <li>",
"      Maxzide&reg;-25",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Triazide&reg;;",
"     </li>",
"     <li>",
"      Nu-Triazide;",
"     </li>",
"     <li>",
"      Pro-Triazide;",
"     </li>",
"     <li>",
"      Riva-Zide;",
"     </li>",
"     <li>",
"      Teva-Triamterene HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is a strong water pill. Sometimes elements (potassium) in the blood may be raised. The chance is greatest in people with high blood sugar (diabetes), kidney disease, very bad illness, and/or in older adults. Your doctor will follow you closely to change the dose to match your body's needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702252",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydrochlorothiazide, triamterene, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High potassium levels or kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking some other water pill that stops potassium loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699071",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low or high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12536 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24373=[""].join("\n");
var outline_f23_51_24373=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179780\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179781\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019497\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019499\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019498\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019503\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019504\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019506\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019501\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019502\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019507\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019508\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/41/34454?source=related_link\">",
"      Hydrochlorothiazide and triamterene: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_51_24374="Pelvic extraperitoneal space";
var content_f23_51_24374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Pelvic extraperitoneal space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 538px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24374=[""].join("\n");
var outline_f23_51_24374=null;
var title_f23_51_24375="Buprenorphine and naloxone: Drug information";
var content_f23_51_24375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Buprenorphine and naloxone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/13/17622?source=see_link\">",
"    see \"Buprenorphine and naloxone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/5/41046?source=see_link\">",
"    see \"Buprenorphine and naloxone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Suboxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13143399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Suboxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Analgesic, Opioid Partial Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Opioid dependence:",
"     </b>",
"     Sublingual:",
"     <b>",
"      Note:",
"     </b>",
"     Buprenorphine and naloxone combination product is not recommended for use during the induction period for long-acting opioids (eg, methadone); initial treatment should begin using buprenorphine oral sublingual tablets under supervision. Patients should be switched to the combination product for maintenance and unsupervised therapy. Doses provided based on buprenorphine content.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Manufacturer&rsquo;s labeling:",
"      </i>",
"     </b>",
"     Maintenance: Target dose: 16 mg daily as a single daily dose; dosage should be adjusted in increments of 2 mg or 4 mg to a level which maintains treatment and suppresses opioid withdrawal symptoms; usual range: 4-24 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Unlabeled dosing recommendations (U.S. Department of Health and Human Services, 2005):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction",
"     </i>",
"     (only administer combination product for induction in patients who are dependent on",
"     <b>",
"      short-acting",
"     </b>",
"     opioids and whose last dose of opioids was &gt;12-24 hours prior to induction):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1 induction dose: Initial: 4 mg; may repeat dose after &gt;2 hours if withdrawal symptoms not relieved; maximum daily dose on day 1: 8 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 2 induction dose: Previous dose from day 1 if no withdrawal symptoms present; if symptoms of withdrawal present, increase day 1 dose by 4 mg. If withdrawal symptoms not relieved after &gt;2 hours, may administer 4 mg; maximum daily dose on day 2: 16 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Subsequent induction days: If withdrawal symptoms are not present, daily dose is established. If withdrawal symptoms are present, increase dose in increments of 2 mg or 4 mg each day as needed for symptom relief. Target daily dose by the end of the first week: 12 mg or 16 mg daily; maximum daily dose: 32 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Stabilization:",
"     </i>",
"     Usual dose: 16-24 mg daily; maximum dose: 32 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Switching between sublingual tablets and sublingual film:",
"     </b>",
"     Same dosage should be used as the previous administered product.",
"     <b>",
"      Note:",
"     </b>",
"     Potential for greater bioavailability with certain sublingual film strengths compared to the same strength of the sublingual tablet; monitor closely for either over- or underdosing when switching patients from one formulation to another.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Switching between sublingual film strengths:",
"     </b>",
"     Systemic exposure may be different with various combinations of sublingual film strengths; pharmacists should not substitute one or more film strengths for another (eg, switching from three 4 mg films to a single 12 mg film, or vice-versa) without physician approval, and patients should be monitored closely for either over- or underdosing when switching between film strengths.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F143152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/5/41046?source=see_link\">",
"      see \"Buprenorphine and naloxone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Opioid dependence:",
"     </b>",
"     Children &ge;16 years: Sublingual tablets: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been adequately studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10952588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate-to-severe impairment: dosage adjustments recommended; however, no specific recommendations are provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Film, sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Suboxone&reg;: Buprenorphine 2 mg and naloxone 0.5 mg (30s); buprenorphine 4 mg and naloxone 1 mg (30s); buprenorphine 8 mg and naloxone 2 mg (30s); buprenorphine 12 mg and naloxone 3 mg (30s) [lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, sublingual: Buprenorphine 2 mg and naloxone 0.5 mg; buprenorphine 8 mg and naloxone 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Suboxone&reg;: Buprenorphine 2 mg and naloxone 0.5 mg [DSC]; buprenorphine 8 mg and naloxone 2 mg [lemon-lime flavor] [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Sublingual tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F143159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prescribing of tablets for opioid dependence is limited to physicians who have met the qualification criteria and have received a DEA number specific to prescribing this product. Tablets will be available through pharmacies and wholesalers which normally provide controlled substances.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10815685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sublingual film: An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM225677.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM225677.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F143133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sublingual film: Film should be placed under the tongue. Keep under the tongue until film dissolves completely; film should not be chewed, swallowed or moved after placement. If more than one film is needed, the additional film should be placed under the tongue on the opposite side from the first film.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sublingual tablet: Tablet should be placed under the tongue until dissolved; should not be swallowed. If two or more tablets are needed per dose, all may be placed under the tongue at once, or two at a time. To ensure consistent bioavailability, subsequent doses should always be taken the same way.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment for opioid dependence",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potential for over- or underdosing when switching among various formulations and between strengths of the sublingual films:",
"       <b>",
"        Not all strengths of sublingual tablets and films are bioequivalent to one another.",
"       </b>",
"       In addition, systemic exposure between the various strengths of sublingual films may be different; pharmacists should not substitute one or more film strengths for another (eg, dispense three 4 mg films for one 12 mg film, or vice-versa) without physician approval. Any patient switching between sublingual tablet and sublingual film formulation or between one or more strengths of the sublingual films should be monitored for over- or underdosing.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (36%), pain (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (8%), erythema (oral mucosa; film), glossodynia (film), oral hypoesthesia (film)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Withdrawal syndrome (25%; placebo 37%), diaphoresis (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (7%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to buprenorphine, naloxone, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic events: Hepatitis has been reported with buprenorphine use; hepatic events ranged from transient, asymptomatic transaminase elevations to hepatic failure; in many cases, patients had preexisting hepatic dysfunction. Monitor liver function tests in all patients prior to and during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity, including bronchospasm, angioneurotic edema, and anaphylactic shock, have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bowel obstruction: Use with caution in patients with a history of ileus or bowel obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol abuse: Use with caution in patients with alcoholism or delirium tremens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with caution in patients with psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion: Healthcare provider should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Combination product is indicated for maintenance therapy for opioid dependence and should not be used for induction. Buprenorphine/naloxone is not appropriate for pain management; deaths have been reported in opioid-naive patients receiving oral buprenorphine for analgesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interchangeability between sublingual film and tablet formulations: Use caution when switching between formulations; potential for greater bioavailability with certain sublingual film strengths compared to the same strength of the sublingual tablet; monitor closely for either over- or underdosing when switching patients from one formulation to another.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interchangeability among sublingual films: Size and compositions of the various strengths of sublingual films are different; various combinations of these strengths may result in different systemic exposure; therefore, pharmacists should not substitute one or more film strengths for another (eg, three 4 mg films compared to one 12 mg film, or vice-versa) without physician approval. Patients should be monitored for over- or underdosing when various film strengths are switched.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Partial antagonist activity of buprenorphine may precipitate acute narcotic withdrawal in opioid-dependent individuals upon rapid discontinuation. Naloxone may precipitate intense withdrawal symptoms in patients addicted to opiates when administered before the opioid effects have subsided, or if misused and administered parenterally by opioid-dependent individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Buprenorphine. Management: Advise patients receiving buprenorphine about the increased risk of CNS depression if they consume alcohol.  Consider alternatives to buprenorphine for opioid addiction treatment in patients who are dependent on alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Mixed Agonist / Antagonist Opioids may diminish the analgesic effect of Analgesics (Opioid).  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Management: Avoid this combination in patients un-boosted atazanavir due to possible decreased atazanavir concentrations.  This combination is not contraindicated in patients also receiving ritonavir, but monitoring for buprenorphine toxicity is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Buprenorphine. Boceprevir may increase the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F143138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Withdrawal has been reported in infants of women receiving buprenorphine during pregnancy. Onset of symptoms ranged from day 1 to day 8 of life, most occurring on day 1.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F143150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Buprenorphine: Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F143139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4663306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Film",
"     </b>",
"     (Suboxone Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-0.5 mg (1): $4.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-1 mg (30): $253.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8-2 mg (1): $8.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12-3 mg (30): $506.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sublingual",
"     </b>",
"     (Buprenorphine HCl-Naloxone HCl Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-0.5 mg (30): $174.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8-2 mg (30): $312.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F143127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests (prior to initiation and during therapy); respiratory status; mental status; CNS depression; symptoms of withdrawal",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Suboxone (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HK, HN, ID, IE, IT, MT, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Absorption is variable among patients following sublingual use, but variability within each individual patient is low.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Potential for greater bioavailability with certain strengths of the sublingual film compared to the same strength of the sublingual tablet. Although pharmacokinetics were similar between the sublingual formulations, bioequivalence is variable. In addition, the sizes and compositions among the sublingual film strengths are different which may result in different systemic exposures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Film: Buprenorphine: 24-42 hours; Naloxone: 2-12 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Center for Substance Abuse Treatment,",
"      <i>",
"       Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction",
"      </i>",
"      , Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 043939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8788 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24375=[""].join("\n");
var outline_f23_51_24375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143145\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13143399\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143157\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143147\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143152\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062967\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682364\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10952588\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143130\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143116\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143159\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217370\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10815685\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143133\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143131\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977973\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143155\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143136\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143119\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298908\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143123\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143125\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143138\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143150\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143139\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663306\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143127\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038544\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143118\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143135\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8788|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/13/17622?source=related_link\">",
"      Buprenorphine and naloxone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/5/41046?source=related_link\">",
"      Buprenorphine and naloxone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_51_24376="Nonepileptic paroxysmal disorders in infancy";
var content_f23_51_24376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonepileptic paroxysmal disorders in infancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/51/24376/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/51/24376/contributors\">",
"     Thien T Nguyen, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/51/24376/contributors\">",
"     Peter W Kaplan, MB, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/51/24376/contributors\">",
"     Angus Wilfong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/51/24376/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/51/24376/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/51/24376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/51/24376/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/51/24376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy is a condition characterized by recurrent seizures. The term seizure refers to a transient occurrence of signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms due to abnormal excessive neuronal activity of the brain.",
"   </p>",
"   <p>",
"    Paroxysmal events are frequent in infancy. In one population-based cohort, they occurred in 9 percent of those in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/1\">",
"     1",
"    </a>",
"    ]. While seizures and epilepsy are commonly considered in the differential, these make up a small fraction (&lt;10 percent) of these events.",
"   </p>",
"   <p>",
"    Neonates and infants exhibit nonepileptic paroxysmal episodes that differ from those encountered in older children and adults (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 1",
"    </a>",
"    ). These may be difficult to differentiate from epileptic events because of the overlapping clinical symptoms as well as the difficulty in interpreting neonatal and infant electroencephalograms (EEG). It is important for clinicians to be aware of and recognize the transient nonepileptic events that resemble seizures in order to avoid unnecessary treatment and to institute the correct treatment when required.",
"   </p>",
"   <p>",
"    This topic reviews nonepileptic paroxysmal events in the neonate and infant.The differential diagnosis of epilepsy in other age groups is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEONATES (BIRTH TO ONE MONTH OF AGE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal neonates commonly exhibit a variety of paroxysmal movements including nonconjugate eye movements, sucking movements without associated eye abnormalities, and sleep-related myoclonus. These normal behaviors as well as the pathologic conditions discussed below can be difficult to distinguish from epileptic seizures, which can also have somewhat subtle manifestations. Electroencephalography (EEG), particularly EEG-monitoring, can be invaluable in distinguishing among these entities. In one study of neonates, 90 percent of abnormal movements suspicious for seizures were found to be nonepileptic on EEG recording [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=see_link\">",
"     \"Clinical features and electrodiagnosis of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apnea, or a pause in breathing for greater than 15 seconds, is usually not due to an epileptic seizure, particularly if apnea is the sole manifestation. Apneic episodes are common in premature children during active sleep and are believed to be due to brainstem immaturity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link\">",
"     \"Management of apnea of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with epileptic seizures, episodes of nonepileptic apnea are more likely to include bradycardia and typically do not include tachycardia or significant alterations in blood pressure, body temperature, or skin color [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. A few jerks may occur, but the baby does not convulse. An epileptic seizure should be suspected if apnea is accompanied by eye closure or opening, eye deviation, mouth movement, hypertension, or tachycardia.",
"   </p>",
"   <p>",
"    When apnea occurs in older infants, it may represent an acute life-threatening event or sudden infant death syndrome (SIDS). In older infants, a search for an underlying etiology should be pursued because apnea may be an important indicator of an underlying neurologic process such as hypoxic-ischemic encephalopathy, intraventricular hemorrhage, hypoglycemia, or a medication effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=see_link\">",
"     \"Apparent life-threatening event in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Jitteriness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jitteriness is a common movement seen in the neonatal period, typically observed as an excessive response to stimulation such as touch or loud noise [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ]. It has a tremulous quality, with a back and forth oscillation of equal amplitude and frequency. In contrast to seizures, the child is typically awake during the events and no associated autonomic disturbance is evident. The movement can be lessened by consoling the child, removing the stimulus, or relaxing the affected limb, interventions that do not affect seizure activity. The provocation of events by stimulus is also atypical for seizures. On the other hand, head or eye deviation during an episode suggests seizure.",
"   </p>",
"   <p>",
"    Mild degrees of jitteriness are common in healthy infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/11\">",
"     11",
"    </a>",
"    ]. More severe jitteriness can interfere with feeding and other aspects of normal infant care. Jitteriness is often associated with drug withdrawal, hypocalcemia, hypoglycemia, and hypoxic-ischemic encephalopathy, conditions that can also produce seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Benign neonatal sleep myoclonus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign neonatal sleep myoclonus refers to a phenomenon of repetitive myoclonic jerks that occur during non-REM sleep in the first few weeks of life and resolve spontaneously by two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The jerks are typically bilateral, symmetric movements of the arms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    legs.",
"   </p>",
"   <p>",
"    Features that help distinguish these myoclonic jerks from epileptic events include the absence of autonomic disturbances, myoclonic jerks occurring only while asleep, and a normal EEG and neurologic and developmental examination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Unlike epileptic seizures, the movement of benign neonatal sleep myoclonus will cease when the baby is aroused. Neonates with severe cerebral dysfunction can also have myoclonic jerks, but these typically occur with a stimulus, or upon wakening or falling asleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperekplexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperekplexia (stiff baby syndrome or startle disease) is a rare genetic disease that has been associated with a variety of gene mutations usually affecting the glycine receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H38#H38\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Hyperekplexia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The disease is characterized by a triad of generalized stiffness while awake, nocturnal myoclonus, and an exaggerated startle reflex. These features are often apparent at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/17\">",
"     17",
"    </a>",
"    ]. Episodes of hypertonia or tonic spasms occur upon awakening or with auditory or tactile stimulus. When severe, these may interfere with breathing and can even cause hypoxic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/19\">",
"     19",
"    </a>",
"    ]. Attacks can be resolved by manual flexion of the neck or hips [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/20\">",
"     20",
"    </a>",
"    ]. All of these features are atypical for epileptic seizures.",
"   </p>",
"   <p>",
"    These tonic spasms can also cause older infants to fall suddenly in response to surprise, sensory stimuli, strong emotion, or stress [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/17\">",
"     17",
"    </a>",
"    ]. As a result, walking is often delayed. The spasms lessen in severity and usually disappear as the child grows older, but an excessive startle response may persist throughout life, elicited even by minor visual, auditory, or tactile stimulus.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"     Clonazepam",
"    </a>",
"    , a gamma aminobutyric acid (GABA) receptor agonist, appears to be effective for alleviating hypertonia and apneic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/17,18,20\">",
"     17,18,20",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    , and sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    also have been cited in the literature as effective therapies for hypertonia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal startle response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942675\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sodium channelopathy causing episodic laryngospasm, along with face and limb myotonia has been described in three neonates, each carrying a de novo mutation of the muscle sodium channel gene SCN4A [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/21\">",
"     21",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/14/21733?source=see_link\">",
"     mexiletine",
"    </a>",
"    was successful in eliminating attacks in two cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INFANTS (ONE MONTH TO ONE YEAR OF AGE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of epileptic seizures in infancy includes events with a broad range of underlying pathologies. Although clinical symptomatology helps to differentiate these from epileptic seizures, electroencephalography (EEG), particularly video-EEG monitoring, can be invaluable in the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Breath-holding spells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breath-holding spells are common events in infants and young children from six months to six years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Most children (80 to 90 percent) with these spells have their first episode before 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/29\">",
"     29",
"    </a>",
"    ]. Rarely, cases first present as neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of these syncopal events is not clear. Some studies support a primary role for dysfunction of the autonomic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/26,27,31\">",
"     26,27,31",
"    </a>",
"    ]. Iron deficiency is more prevalent in children with breath-holding spells compared with controls and appears to contribute to the occurrence of breath-holding spells and the underlying dysautonomia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. A family history of breath-holding spells is present in 20 to 35 percent of patients and an autosomal dominant trait has been reported in some families [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/29,34\">",
"     29,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two clinical types of breath-holding spells are cyanotic and pallid. Both family members and individual children can demonstrate both types, but usually one predominates [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cyanotic breath-holding spells",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the cyanotic variety, the child becomes angry or upset in response to a reprimand or a mild injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/28\">",
"     28",
"    </a>",
"    ]. The precipitant is often minimal, even trivial. There is a brief period of crying, typically followed quickly by breath-holding in forced expiration with apnea and cyanosis, which is then often followed by limpness and loss of consciousness. Cyanosis can appear faster than anticipated with simple breath-holding; and the loss of tone often is striking. The sequence is quite reproducible.",
"   </p>",
"   <p>",
"    If the apnea is prolonged, there may be other clinical manifestations, including decorticate or decerebrate posturing. A few children have generalized motor seizures characterized by increased tone followed by loss of tone or clonic activity and prolonged postictal unconsciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Status epilepticus has been reported.",
"   </p>",
"   <p>",
"    A significant minority of children (15 to 25 percent) have multiple episodes daily [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Most children have one to six spells per week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pallid breath-holding spells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pallid infantile syncope is less common than the cyanotic variety and is more likely to be mistaken for a seizure. The child typically loses consciousness after a minor fall or blow to the head or upper body [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/28\">",
"     28",
"    </a>",
"    ]. Often, this history is not volunteered by the patient or family and must be elicited by direct questioning. The loss of consciousness may be delayed up to 30 seconds after the minor trauma, obscuring the connection between the two events. The child then stops breathing and becomes pale, diaphoretic, and limp. If the episode lasts more than a few seconds, this is followed by generalized increased tone of the trunk and extremities, often with incontinence and occasionally, low amplitude clonus. The entire episode lasts less than one minute, but the child is confused",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sleepy for several minutes afterward.",
"   </p>",
"   <p>",
"    The event is caused by cardiac bradycardia. Events may be reproduced with 10 seconds of ocular pressure during electrocardiogram (ECG) monitoring, which produces a typical attack with a profound bradycardia, even asystole, usually lasting 5 to 10 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/28\">",
"     28",
"    </a>",
"    ]. Cases have been described in which the heart beat did not return for 30 seconds. If simultaneous electroencephalography (EEG) monitoring is performed, hypersynchronous, high amplitude slowing may be observed, followed by flattening if the episode is prolonged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no diagnostic test that confirms the diagnosis of breath-holding spells. These may be difficult to distinguish from epileptic seizures. A history of any provocation (eg, head injury, crying) should be elicited, as this is typical for breath-holding spells, but not epileptic seizure. Prominent color change, pallor or cyanosis, also suggests breath-holding spells rather than seizures. As with other nonepileptic events, video-EEG monitoring can be helpful in difficult cases.",
"   </p>",
"   <p>",
"    Other causes of syncope also should be considered. If the episodes are prolonged or frequent, precipitated by startle or other nontraumatic stimuli, or if a family history of syncope or sudden death exists, a more in-depth cardiac evaluation, particularly for prolonged QT syndrome, is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=see_link\">",
"     \"Causes of syncope in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because iron deficiency anemia is highly associated with breath-holding spells, evaluation with complete blood count and serum ferritin is warranted in these children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prognosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for children with breath-holding spells is excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/29\">",
"     29",
"    </a>",
"    ]. The median age of remission is four years; virtually all children stop having episodes by eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/27-29,39\">",
"     27-29,39",
"    </a>",
"    ]. Neurologic development is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron supplementation in anemic or iron-deficient patients appears to reduce the frequency of breath-holding attacks, according to observational studies and one clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/34,38,41,42\">",
"     34,38,41,42",
"    </a>",
"    ]. Complete remission of spells reportedly occurs in 32 to 52 percent. A typical dose is 5 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of ferrous sulphate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/38\">",
"     38",
"    </a>",
"    ]. The duration of treatment should be individualized according to the improvement of clinical episodes and the anemia. The value of iron supplementation in children with breath holding spells who are not anemic has not been well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiepileptic drugs are not helpful in reducing the breath-holding spells, but may or may not prevent secondary anoxic seizures if these are frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/29,43\">",
"     29,43",
"    </a>",
"    ]. The GABA-derivative, piracetam (40 or 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses) was shown in two randomized trials (one unblinded) to reduce the frequency of breath-holding spells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. This drug is not available in the United States.",
"   </p>",
"   <p>",
"    In rare patients with severe attacks of pallid infantile syncope associated with prolonged, severe bradycardia or asystole,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    and cardiac pacing have been employed to reduce the frequency of spells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/29,46,47\">",
"     29,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Benign myoclonus of infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign myoclonus of infancy is also known as benign nonepileptic infantile spasms. The spasms can manifest as myoclonus, spasms with brief tonic contractions, shuddering,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atonia (negative myoclonus) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/48\">",
"     48",
"    </a>",
"    ]. Spasms occur in clusters, frequently at mealtime. First occurring at three to eight months of age, these clusters increase in intensity and severity over weeks or months and then remit spontaneously at two to three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of these attacks may be clinically indistinguishable from other types of progressive infantile spasms associated with mental retardation and epileptic seizures, although they typically occur only while awake [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/48,49,51\">",
"     48,49,51",
"    </a>",
"    ]. Benign myoclonus of infancy can be identified by a normal EEG and normal neurologic development without subsequent epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link\">",
"     \"Clinical features and diagnosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Shuddering attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shuddering attacks usually begin in infancy, less commonly in childhood. These brief episodes of altered muscle tone often manifest as a rapid tremor of the head, shoulder, and trunk reminiscent of a \"shudder\" or \"shiver\" from a chill. There may be stiffening, flexion, and elevation of the arms with a low-amplitude tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/52\">",
"     52",
"    </a>",
"    ]. If seated, the child may lean in one direction or even fall. The child may stare, appear to be unaware of the surroundings, and then promptly return to the task at hand [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The episodes last a few seconds, and can occur multiple times a day [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. The spells often occur with feeding, or when the child is excited or distressed, suggesting they are a pattern of stimulus overflow in a young child. They never occur during sleep and virtually never when being held and cuddled.",
"   </p>",
"   <p>",
"    The EEG during the spells is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Neurologic and developmental examinations also are normal.",
"   </p>",
"   <p>",
"    The episodes may continue at lower frequency into the second half of the first decade and can, on rare occasions, cause the child to fall in the middle of activities such as playing ball. Occasionally, a family history of benign essential tremor exists, but the children themselves do not have a chronic tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/55\">",
"     55",
"    </a>",
"    ]. The spells spontaneously resolve by the second decade without treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sandifer syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sandifer syndrome refers to the intermittent paroxysmal spells of generalized stiffening and opisthotonic posturing that are caused by gastroesophageal reflux in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The posturing likely reflects a pain response to acidic reflux into the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/54\">",
"     54",
"    </a>",
"    ]. These spells may be associated with apnea, staring, and minimal jerking of the extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/58\">",
"     58",
"    </a>",
"    ]. A careful history will reveal that these spells are associated with feedings, usually occurring within 30 minutes following a meal. Sandifer syndrome can be seen in normal children, as well as children with hypotonia and tracheomalacia.",
"   </p>",
"   <p>",
"    If the history suggests Sandifer syndrome, a gastroesophageal work-up should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/54,57\">",
"     54,57",
"    </a>",
"    ]. Treatment of gastrointestinal reflux reduces the frequency and severity of attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=see_link&amp;anchor=H9#H9\">",
"     \"Acquired torticollis in children\", section on 'Sandifer syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dystonia is an abnormal posture due to sustained contraction of both the agonist and antagonist muscle groups. A dystonic posture may be generalized or focal; examples include opisthotonic posturing, torticollis, and oculogyric crisis.",
"   </p>",
"   <p>",
"    A common etiology of dystonia in infants is an acute reaction to drugs such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , phenothiazines, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H12#H12\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Acute dystonic reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Benign paroxysmal torticollis in infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is an idiopathic disorder, characterized by periods of an abnormal, sustained posture of the head and neck in which the head tilts to one side, with the face rotated toward the opposite side. The events begin and end suddenly, with a duration between a few hours and a few days. The child is alert and responsive during an attack. Episodes usually first occur in the first three months of life and may recur at varying intervals, resolving by the age of three years in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. EEG and neurologic examinations are normal, as is subsequent neurologic development; any delays in motor development improve with resolution of episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/61\">",
"     61",
"    </a>",
"    ]. No treatment is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=see_link&amp;anchor=H7#H7\">",
"     \"Acquired torticollis in children\", section on 'Benign paroxysmal torticollis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A relationship between this disorder and migraine is suggested. A family history of migraines is common in children with this disorder and they may develop migraine later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. In one family, benign paroxysmal torticollis appeared to be associated with inheritance of a CACN1A mutation, which is also linked to familial hemiplegic migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Abnormal eye movements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oculomotor apraxia is a condition with impaired saccadic eye movements in which the child will turn his head suddenly so as to move the direction of gaze. These peculiar rapid head movements are rarely mistaken for epileptic seizure. Oculomotor apraxia may be seen in ataxia telangiectasia and lysosomal storage diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link&amp;anchor=H15#H15\">",
"     \"Ataxia-telangiectasia\", section on 'Ataxia-ocular apraxia type 1'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link&amp;anchor=H16#H16\">",
"     \"Ataxia-telangiectasia\", section on 'Ataxia-ocular apraxia type 2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spasmus nutans consists of a triad of nystagmus, head nodding (titubation), and head tilt. When the symptoms fluctuate during the course of the day, they may be confused with epileptic seizures. Consciousness is not impaired. The onset is usually the first few months of life and resolves by five years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1034?source=see_link&amp;anchor=H9#H9\">",
"     \"Pendular nystagmus\", section on 'Spasmus nutans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opsoclonus consists of rapid, erratic, involuntary conjugate eye movements (\"dancing eyes\"). These eye movements are usually associated with myoclonus and ataxia, also described as dancing eyes-dancing feet syndrome. Most cases occur between ages 6 and 18 months. Fifty percent of cases are related to an underlying neoplasm, especially neuroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H31#H31\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Myoclonus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rhythmic movement disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhythmic movements such as nocturnal head banging, body rocking, and head rolling typically occur in children younger than one year of age as they try to fall asleep [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24376/abstract/13,65,66\">",
"     13,65,66",
"    </a>",
"    ]. They also can be present in deep sleep and in wakefulness. Episodes usually begin in infancy and resolve by five years of age, but can persist into adult life. The characteristic nature of the movements is not typical for epilepsy, and patients often can be directed to stop the movements, which is generally not true for an epileptic seizure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of epileptic seizures in neonates and infants includes a variety of benign, physiologic phenomena as well as pathologic conditions (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 1",
"    </a>",
"    ). Some of these conditions can persist into childhood and longer.",
"   </p>",
"   <p>",
"    Clinical features of these events help distinguish these from epileptic seizures (see descriptions of individual disorders, above). These include the setting in which the event occurred, particularly the presence or absence of provocation. Associated features: change in vital signs, color change, autonomic disturbances, loss of consciousness, and head and eye deviation are important diagnostically as is the baseline neurologic and developmental examination. In difficult cases, electroencephalography (EEG), particularly video-EEG monitoring is useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=see_link\">",
"     \"Clinical features and electrodiagnosis of neonatal seizures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/1\">",
"      Visser AM, Jaddoe VW, Arends LR, et al. Paroxysmal disorders in infancy and their risk factors in a population-based cohort: the Generation R Study. Dev Med Child Neurol 2010; 52:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/2\">",
"      Scher MS, Painter MJ. Controversies concerning neonatal seizures. Pediatr Clin North Am 1989; 36:281.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe, JJ. Neurology of the Newborn, 4th ed, WB Saunders Co, Philadelphia 2001.",
"    </li>",
"    <li>",
"     Kaplan, PW, Fisher, RS. Imitators of Epilepsy, 2nd ed, Demos Medical Publishing, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/5\">",
"      Watanabe K, Hara K, Hakamada S, et al. Seizures with apnea in children. Pediatrics 1982; 70:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/6\">",
"      Thach BT. Sleep apnea in infancy and childhood. Med Clin North Am 1985; 69:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/7\">",
"      O'Regan ME, Brown JK. Abnormalities in cardiac and respiratory function observed during seizures in childhood. Dev Med Child Neurol 2005; 47:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/8\">",
"      Fenichel GM, Olson BJ, Fitzpatrick JE. Heart rate changes in convulsive and nonconvulsive neonatal apnea. Ann Neurol 1980; 7:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/9\">",
"      Parker S, Zuckerman B, Bauchner H, et al. Jitteriness in full-term neonates: prevalence and correlates. Pediatrics 1990; 85:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/10\">",
"      Armentrout DC, Caple J. The jittery newborn. J Pediatr Health Care 2001; 15:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/11\">",
"      Shuper A, Zalzberg J, Weitz R, Mimouni M. Jitteriness beyond the neonatal period: a benign pattern of movement in infancy. J Child Neurol 1991; 6:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/12\">",
"      Di Capua M, Fusco L, Ricci S, Vigevano F. Benign neonatal sleep myoclonus: clinical features and video-polygraphic recordings. Mov Disord 1993; 8:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/13\">",
"      Walters AS. Clinical identification of the simple sleep-related movement disorders. Chest 2007; 131:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/14\">",
"      Paro-Panjan D, Neubauer D. Benign neonatal sleep myoclonus: experience from the study of 38 infants. Eur J Paediatr Neurol 2008; 12:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/15\">",
"      Egger J, Grossmann G, Auchterlonie IA. Benign sleep myoclonus in infancy mistaken for epilepsy. BMJ 2003; 326:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/16\">",
"      Andrew M, Owen MJ. Hyperekplexia: abnormal startle response due to glycine receptor mutations. Br J Psychiatry 1997; 170:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/17\">",
"      Bakker MJ, van Dijk JG, van den Maagdenberg AM, Tijssen MA. Startle syndromes. Lancet Neurol 2006; 5:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/18\">",
"      Zhou L, Chillag KL, Nigro MA. Hyperekplexia: a treatable neurogenetic disease. Brain Dev 2002; 24:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/19\">",
"      Giacoia GP, Ryan SG. Hyperekplexia associated with apnea and sudden infant death syndrome. Arch Pediatr Adolesc Med 1994; 148:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/20\">",
"      Praveen V, Patole SK, Whitehall JS. Hyperekplexia in neonates. Postgrad Med J 2001; 77:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/21\">",
"      Lion-Francois L, Mignot C, Vicart S, et al. Severe neonatal episodic laryngospasm due to de novo SCN4A mutations: a new treatable disorder. Neurology 2010; 75:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/22\">",
"      Kotagal P, Costa M, Wyllie E, Wolgamuth B. Paroxysmal nonepileptic events in children and adolescents. Pediatrics 2002; 110:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/23\">",
"      Watemberg N, Tziperman B, Dabby R, et al. Adding video recording increases the diagnostic yield of routine electroencephalograms in children with frequent paroxysmal events. Epilepsia 2005; 46:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/24\">",
"      Bye AM, Kok DJ, Ferenschild FT, Vles JS. Paroxysmal non-epileptic events in children: a retrospective study over a period of 10 years. J Paediatr Child Health 2000; 36:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/25\">",
"      Lombroso CT, Lerman P. Breathholding spells (cyanotic and pallid infantile syncope). Pediatrics 1967; 39:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/26\">",
"      DiMario FJ Jr. Breath-holding spells in childhood. Am J Dis Child 1992; 146:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/27\">",
"      DiMario FJ Jr, Burleson JA. Autonomic nervous system function in severe breath-holding spells. Pediatr Neurol 1993; 9:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/28\">",
"      Breningstall GN. Breath-holding spells. Pediatr Neurol 1996; 14:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/29\">",
"      DiMario FJ Jr. Prospective study of children with cyanotic and pallid breath-holding spells. Pediatrics 2001; 107:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/30\">",
"      Breukels MA, Pl&ouml;tz FB, van Nieuwenhuizen O, van Diemen-Steenvoorde JA. Breath holding spells in a 3-day-old neonate: an unusual early presentation in a family with a history of breath holding spells. Neuropediatrics 2002; 33:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/31\">",
"      Kolkiran A, Tutar E, Atalay S, et al. Autonomic nervous system functions in children with breath-holding spells and effects of iron deficiency. Acta Paediatr 2005; 94:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/32\">",
"      H&uuml;daoglu O, Dirik E, Yi U, Kurul S. Parental attitude of mothers, iron deficiency anemia, and breath-holding spells. Pediatr Neurol 2006; 35:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/33\">",
"      Orii KE, Kato Z, Osamu F, et al. Changes of autonomic nervous system function in patients with breath-holding spells treated with iron. J Child Neurol 2002; 17:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/34\">",
"      DiMario FJ Jr, Sarfarazi M. Family pedigree analysis of children with severe breath-holding spells. J Pediatr 1997; 130:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/35\">",
"      Moorjani, BI, Rothner, AD, Kotagal, P. Breath-holding spells and prolonged seizures. Ann Neurol 1995; 38:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/36\">",
"      Kuhle S, Tiefenthaler M, Seidl R, Hauser E. Prolonged generalized epileptic seizures triggered by breath-holding spells. Pediatr Neurol 2000; 23:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/37\">",
"      Allan WC, Gospe SM Jr. Seizures, syncope, or breath-holding presenting to the pediatric neurologist--when is the etiology a life-threatening arrhythmia? Semin Pediatr Neurol 2005; 12:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/38\">",
"      Boon R. Does iron have a place in the management of breath holding spells? Arch Dis Child 2002; 87:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/39\">",
"      Goraya JS, Virdi VS. Persistence of breath-holding spells into late childhood. J Child Neurol 2001; 16:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/40\">",
"      Haverkamp F, Noeker M. Traditional view empirically revisited: normal intellectual functioning in breath holding spells. Eur J Pediatr 1998; 157:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/41\">",
"      Mocan H, Yildiran A, Orhan F, Erduran E. Breath holding spells in 91 children and response to treatment with iron. Arch Dis Child 1999; 81:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/42\">",
"      Zehetner AA, Orr N, Buckmaster A, et al. Iron supplementation for breath-holding attacks in children. Cochrane Database Syst Rev 2010; :CD008132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/43\">",
"      Horrocks IA, Nechay A, Stephenson JB, Zuberi SM. Anoxic-epileptic seizures: observational study of epileptic seizures induced by syncopes. Arch Dis Child 2005; 90:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/44\">",
"      Donma MM. Clinical efficacy of piracetam in treatment of breath-holding spells. Pediatr Neurol 1998; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/45\">",
"      Sawires H, Botrous O. Double-blind, placebo-controlled trial on the effect of piracetam on breath-holding spells. Eur J Pediatr 2012; 171:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/46\">",
"      Kelly AM, Porter CJ, McGoon MD, et al. Breath-holding spells associated with significant bradycardia: successful treatment with permanent pacemaker implantation. Pediatrics 2001; 108:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/47\">",
"      DiMario FJ Jr. Breath-holding spells and pacemaker implantation. Pediatrics 2001; 108:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/48\">",
"      Caraballo RH, Capovilla G, Vigevano F, et al. The spectrum of benign myoclonus of early infancy: Clinical and neurophysiologic features in 102 patients. Epilepsia 2009; 50:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/49\">",
"      Maydell BV, Berenson F, Rothner AD, et al. Benign myoclonus of early infancy: an imitator of West's syndrome. J Child Neurol 2001; 16:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/50\">",
"      Lombroso CT, Fejerman N. Benign myoclonus of early infancy. Ann Neurol 1977; 1:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/51\">",
"      Donat JF, Wright FS. Clinical imitators of infantile spasms. J Child Neurol 1992; 7:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/52\">",
"      Holmes GL, Russman BS. Shuddering attacks. Evaluation using electroencephalographic frequency modulation radiotelemetry and videotape monitoring. Am J Dis Child 1986; 140:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/53\">",
"      Kanazawa O. Shuddering attacks-report of four children. Pediatr Neurol 2000; 23:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/54\">",
"      Frankel EA, Shalaby TM, Orenstein SR. Sandifer syndrome posturing: relation to abdominal wall contractions, gastroesophageal reflux, and fundoplication. Dig Dis Sci 2006; 51:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/55\">",
"      Vanasse M, Bedard P, Andermann F. Shuddering attacks in children: an early clinical manifestation of essential tremor. Neurology 1976; 26:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/56\">",
"      Lehwald N, Krausch M, Franke C, et al. Sandifer syndrome--a multidisciplinary diagnostic and therapeutic challenge. Eur J Pediatr Surg 2007; 17:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/57\">",
"      Kabaku N, Kurt A. Sandifer Syndrome: a continuing problem of misdiagnosis. Pediatr Int 2006; 48:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/58\">",
"      Sheikh S, Stephen TC, Sisson B. Prevalence of gastroesophageal reflux in infants with recurrent brief apneic episodes. Can Respir J 1999; 6:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/59\">",
"      Cohen HA, Nussinovitch M, Ashkenasi A, et al. Benign paroxysmal torticollis in infancy. Pediatr Neurol 1993; 9:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/60\">",
"      Drigo P, Carli G, Laverda AM. Benign paroxysmal torticollis of infancy. Brain Dev 2000; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/61\">",
"      Rosman NP, Douglass LM, Sharif UM, Paolini J. The neurology of benign paroxysmal torticollis of infancy: report of 10 new cases and review of the literature. J Child Neurol 2009; 24:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/62\">",
"      Giffin NJ, Benton S, Goadsby PJ. Benign paroxysmal torticollis of infancy: four new cases and linkage to CACNA1A mutation. Dev Med Child Neurol 2002; 44:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/63\">",
"      Bleasel A, Kotagal P. Paroxysmal nonepileptic disorders in children and adolescents. Semin Neurol 1995; 15:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/64\">",
"      Posner JB. Autoantibodies in childhood opsoclonus-myoclonus syndrome. J Pediatr 1997; 130:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/65\">",
"      Manni R, Terzaghi M. Rhythmic movements during sleep: a physiological and pathological profile. Neurol Sci 2005; 26 Suppl 3:s181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24376/abstract/66\">",
"      Derry CP, Duncan JS, Berkovic SF. Paroxysmal motor disorders of sleep: the clinical spectrum and differentiation from epilepsy. Epilepsia 2006; 47:1775.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6210 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-213.134.24.46-B0B7A2AA67-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24376=[""].join("\n");
var outline_f23_51_24376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEONATES (BIRTH TO ONE MONTH OF AGE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Jitteriness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Benign neonatal sleep myoclonus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperekplexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1942675\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INFANTS (ONE MONTH TO ONE YEAR OF AGE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Breath-holding spells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cyanotic breath-holding spells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pallid breath-holding spells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Benign myoclonus of infancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Shuddering attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sandifer syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dystonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Benign paroxysmal torticollis in infancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Abnormal eye movements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rhythmic movement disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6210\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6210|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/38/32364\" title=\"table 1\">",
"      Differential diagnosis of seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=related_link\">",
"      Acquired torticollis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31272?source=related_link\">",
"      Apparent life-threatening event in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36007?source=related_link\">",
"      Causes of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=related_link\">",
"      Clinical features and diagnosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=related_link\">",
"      Clinical features and electrodiagnosis of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=related_link\">",
"      Nonepileptic paroxysmal disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1034?source=related_link\">",
"      Pendular nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_51_24377="Kikuchis disease lymph node histopathology 1";
var content_f23_51_24377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Lymph node from a patient with Kikuchi's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Haematoxylin &amp; eosin stained lymph node at 40x magnification, showing areas of necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Anthony Landgren.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24377=[""].join("\n");
var outline_f23_51_24377=null;
var title_f23_51_24378="Overview of the management of hepatitis B and case examples";
var content_f23_51_24378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of hepatitis B and case examples",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/51/24378/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/51/24378/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/51/24378/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/51/24378/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/51/24378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/51/24378/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/51/24378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following topic review will summarize issues related to the management of hepatitis B. These recommendations (and the data supporting them) are discussed in detail on their corresponding topic reviews. In addition, the recommendations below are generally consistent with guidelines from the European consensus statement (EASL), Asian-Pacific consensus statement, and American Association for the Study of Liver Diseases Practice Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific examples of cases are described at the end, which illustrate some of the issues that may arise when making treatment decisions for patients with chronic hepatitis B. Clinical decisions regarding individual patients should be based upon patient-specific clinical information and test results. Data supporting this section are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEPATITIS B VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatitis B virus (HBV) is a double-stranded DNA virus belonging to the family of hepadnaviruses, which include duck hepatitis virus, woodchuck hepatitis virus, and ground squirrel hepatitis virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=see_link\">",
"     \"Characteristics of the hepatitis B virus and pathogenesis of infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HBV has traditionally been classified into eight genotypes (A to H) based upon an inter-group divergence of 8 percent or more in the complete nucleotide sequence. The prevalence of specific genotypes varies geographically. Furthermore, genotypes may correlate with clinical course and response to interferon. Genotype testing is not necessary in routine clinical practice, but it may be indicated for HBeAg-positive patients who are considering interferon therapy since patients with genotype A have a more favorable response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6250?source=see_link\">",
"     \"Clinical significance and molecular characteristics of common hepatitis B virus variants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus infection is a global public health problem. It is estimated that there are more than 300 million HBV carriers in the world, of whom approximately 500,000 die annually from HBV-related liver disease. Despite the availability of HBV vaccines, the rate of HBV-related hospitalizations, cancers, and deaths in the United States have more than doubled during the past decade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WHO SHOULD BE TESTED",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for HBV have been identified, providing a rationale for screening (",
"    <a class=\"graphic graphic_table graphicRef55052 \" href=\"UTD.htm?29/43/30396\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62806 \" href=\"UTD.htm?6/43/6838\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Testing should include HBsAg and anti-HBs. Patients who are negative for these markers should be vaccinated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link\">",
"     \"Immunizations for patients with chronic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation of patients with chronic HBV infection should include (",
"    <a class=\"graphic graphic_table graphicRef62875 \" href=\"UTD.htm?19/48/20236\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history and physical examination, emphasizing risk factors for coinfection with HCV",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HIV, use of alcohol, and family history of HBV infection and liver disease.",
"     </li>",
"     <li>",
"      Laboratory tests: complete blood count with platelets, liver biochemical tests (AST, ALT, total bilirubin, alkaline phosphatase, albumin), prothrombin time, and tests for HBV replication (HBeAg, anti-HBe, HBV DNA). Testing for immunity to hepatitis A virus (HAV) with HAV IgG antibody should be considered in patients who are not known to be immune.",
"     </li>",
"     <li>",
"      Evaluation for other causes of liver disease including hepatitis C, hepatitis D, and hemochromatosis by obtaining anti-HCV, anti-HDV (in injection drug users and persons from countries where HDV is endemic, particularly Eastern Europe, Mediterranean countries, and the Amazon basin), iron, and TIBC.",
"     </li>",
"     <li>",
"      Screening for HIV infection in persons with risk factors such as injection drug use, multiple sexual exposures, or men who have sex with men.",
"     </li>",
"     <li>",
"      Screening for hepatocellular carcinoma if indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link\">",
"       \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liver biopsy may be considered for patients who meet criteria for chronic hepatitis (ie, HBsAg positive for &gt;6 months, serum HBV DNA &gt;10(5)",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      or &gt;20,000 int.",
"      <span class=\"nowrap\">",
"       unit/mL,",
"      </span>",
"      persistent or intermittent elevation in",
"      <span class=\"nowrap\">",
"       ALT/AST",
"      </span>",
"      levels). Liver biopsy is most important for patients who do not meet current criteria for treatment but have serum HBV DNA &gt;10(4) to 10(5)",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (2000 to 20,000 int.",
"      <span class=\"nowrap\">",
"       unit/mL)",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       ALT/AST",
"      </span>",
"      levels that are normal or mildly elevated (&lt;2x upper limit); patients with histologically active or advanced liver disease may benefit from treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link\">",
"       \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A normal serum ALT level alone in patients with active viral replication does",
"      <strong>",
"       not",
"      </strong>",
"      predict mild or normal histologic findings [",
"      <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. One report found that up to 37 percent of patients with persistently normal ALT and HBV DNA levels &gt;10,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (approximately &gt;2000 int.",
"      <span class=\"nowrap\">",
"       unit/mL)",
"      </span>",
"      had significant fibrosis and inflammation on liver biopsy. On subgroup analysis, most such patients had an ALT in the high range of normal and were older than 40. By contrast, two studies in patients in the immune tolerant phase of chronic HBV infection found that despite high HBV DNA levels, most patients had no or minimal fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Considered together, these data indicate that age or duration of infection is important in predicting severity of liver injury in patients with high HBV DNA but normal ALT levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     WHO SHOULD BE TREATED AND HOW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for treatment in patients with chronic HBV is to reduce the risk of progressive chronic liver disease, transmission to others, and other long-term complications from chronic HBV such as cirrhosis and hepatocellular carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that treatment be considered in patients with HBeAg positive or HBeAg negative chronic hepatitis. Patients with compensated cirrhosis and HBV DNA &gt;2000 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    and those with decompensated cirrhosis and detectable HBV DNA by PCR assay should be considered for antiviral therapy, regardless of the serum ALT level.",
"   </p>",
"   <p>",
"    The following criteria for treatment were suggested in a 2008 consensus conference from the United States National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients in whom therapy is indicated: acute liver failure, clinical complications of cirrhosis, cirrhosis or advanced fibrosis with high serum HBV DNA, or prevention of reactivation of chronic HBV during chemotherapy or immunosuppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients for whom therapy may be indicated: patients in the immune-active phase who do not have advanced fibrosis or cirrhosis (HBeAg-positive or HBeAg-negative chronic hepatitis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients for whom immediate therapy is not routinely indicated: (1) Patients with chronic HBV in the immune tolerant phase (with high levels of serum HBV DNA but normal serum ALT levels or little activity on liver biopsy); (2) Patients in the inactive carrier phase (with persistently low levels of or no detectable HBV DNA in serum and normal serum ALT levels); (3) Patients who have latent HBV infection (HBV DNA without HBsAg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations from the American Association for the Study of Liver Diseases updated in 2009 suggest an approach and considerations for treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef80264 \" href=\"UTD.htm?24/45/25311\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58520 \" href=\"UTD.htm?26/32/27149\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Recommendations from the European Association for the Study of the Liver (EASL) that were updated in 2012 suggest patients be considered for treatment when they have HBV DNA levels greater than 2000 int.",
"    <span class=\"nowrap\">",
"     unit/mL,",
"    </span>",
"    have serum ALT levels above the upper limit of normal, and evidence of moderate to severe necroinflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    at least moderate fibrosis on liver biopsy (or assessed using a validated non-invasive marker) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/3\">",
"     3",
"    </a>",
"    ]. The guidelines specify various patient types and cutoff values for HBV DNA and ALT that need to be considered in making treatment recommendations. The full guideline is available online (",
"    <a class=\"external\" href=\"file://www.easl.eu/_clinical-practice-guideline\">",
"     file://www.easl.eu/_clinical-practice-guideline",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HBeAg-positive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is recommended for those with HBV DNA &gt;20,000 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    and ALT &gt;2 x ULN in patients without cirrhosis. As noted above, patients with compensated cirrhosis and HBV DNA &gt;2000 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    and those with decompensated cirrhosis and detectable HBV DNA by PCR assay should be considered for antiviral therapy, regardless of the serum ALT level. Treatment should be delayed for three to six months in newly diagnosed HBeAg positive patients with compensated liver disease to determine whether spontaneous HBeAg seroconversion will occur. Patients with chronic hepatitis whose serum ALT is persistently below two times the upper limit of normal can be observed, considering treatment if and when the serum ALT becomes higher. Possible exceptions to this rule are those who have recurrent hepatitis flares that fail to clear HBeAg, patients with icteric flares, those with active or advanced histologic findings (such as",
"    <span class=\"nowrap\">",
"     moderate/severe",
"    </span>",
"    inflammation or bridging",
"    <span class=\"nowrap\">",
"     fibrosis/cirrhosis),",
"    </span>",
"    and patients above the age of 40 who remain HBeAg positive with persistently high HBV DNA levels.",
"   </p>",
"   <p>",
"    Treatment may also be indicated in patients with HBV-related polyarteritis nodosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although treatment can lead to virus suppression in HBeAg positive patients with normal ALT, the likelihood of HBeAg seroconversion is low. The benefits of long-term treatment in such patients, most of whom are young Asians with perinatally acquired HBV infection, must be balanced against the risks of drug-resistance, side effects, and costs, particularly since some of these individuals will undergo spontaneous HBeAg seroconversion and remain in remission for many years afterwards, and since most of these individuals will have very low rates of treatment-related HBeAg seroconversion",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HBeAg-negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment may be initiated immediately once a diagnosis of HBeAg negative chronic hepatitis (ALT &gt;2 x ULN and HBV DNA &gt;2000 int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    is established because sustained remission is rare in the absence of treatment. Because of the fluctuating course of HBeAg negative chronic hepatitis, serial follow-up is needed to differentiate an inactive carrier state from HBeAg negative chronic hepatitis. Liver biopsy should be considered in HBeAg negative patients who have serum HBV DNA levels &gt;2000 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    and normal or mildly elevated ALT to determine if treatment is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Choosing among the available options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment strategies for chronic HBV include interferon (standard and pegylated),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (in countries in which it is approved) (",
"    <a class=\"graphic graphic_table graphicRef52919 graphicRef72908 graphicRef68258 \" href=\"UTD.htm?10/17/10527\">",
"     table 4A-C",
"    </a>",
"    ). The following are general rules that can be considered when deciding upon an approach in individual settings. Specific examples are presented in the cases below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of interferon compared to the other options are its finite duration of treatment, the absence of selection of resistant mutants, and a more durable response. On the other hand, side effects from interferon are troubling for many patients, and (less commonly) can be severe. Furthermore, interferon cannot be used in patients with decompensated disease. The main role of interferon is primarily treatment of young patients with well compensated liver disease who do not wish to be on long-term treatment or are planning to be pregnant within the next two to three years. Interferon is also an attractive option for patients with HBV genotype A infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lamivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main advantages of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    are its lower cost compared to the other oral agents and the many years of experience confirming its safety, including its use during pregnancy. Compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , lamivudine has more rapid and more potent virus suppression, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    are superior to lamivudine in suppressing viral replication. The main disadvantage of lamivudine is the high rate of drug resistance. The role of lamivudine in the care of HBV is diminishing with the availability of new therapies which are associated with lower rates of drug resistance. Lamivudine may still have a role in patients coinfected with HIV (in whom lamivudine may be part of the antiretroviral regimen which contains a second drug with anti-HBV activity such as tenofovir). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Adefovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    is its activity against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV and a lower rate of drug resistance compared to lamivudine. However, virus suppression is slow at the approved dose and up to 25 percent of patients experience minimal or no viral suppression. Adefovir at high doses has been associated with nephrotoxicity. At the approved dose of 10 mg daily, reversible increase in serum creatinine has been reported in 3 to 9 percent of patients after four to five years of treatment. Adefovir resistance was not detected after one year of treatment but the rate of drug resistance has been reported to be as high as 29 percent after five years of treatment. The most important role of adefovir is in the treatment of patients with lamivudine-resistant HBV, preferably in combination. With the approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , which is more potent, the role of adefovir is rapidly diminishing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Entecavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main advantages of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    are its potent antiviral activity and a low rate of drug resistance. Entecavir has a more important role in primary treatment of HBV than in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV. Entecavir may also have an important role in patients with decompensated cirrhosis because of its potent antiviral activity and low rate of drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    is rare among nucleoside-na&iuml;ve patients (approximately 1 percent with up to five years of treatment). By contrast, resistance has been observed in up to 50 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -refractory patients after five years of treatment. Studies in rodents (that used 24 to 40 fold higher doses of entecavir than in humans) have reported increased rates of tumors; the relevance of these findings to humans is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Telbivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     Telbivudine",
"    </a>",
"    appears to have slightly more potent antiviral effects compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    but it selects for the same resistant mutants as lamivudine and is more expensive. Thus, its role as primary therapy is limited. Furthermore, there have been rare cases of myopathy and peripheral neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    has more potent antiviral activity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    and is effective in suppressing wild-type as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV. Tenofovir may be used as first line treatment in treatment-na&iuml;ve patients, and in patients with lamivudine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    resistance, preferably as additional treatment in these patients. Tenofovir can also be used to substitute for adefovir in patients who have inadequate viral response to adefovir. However, its efficacy in patients with adefovir-resistant HBV is limited. Tenofovir has replaced adefovir in countries where it is approved because of its more potent antiviral activity. Preliminary data indicate that resistance to tenofovir is rare after up to five years of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prediction of response HBeAg positive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For HBeAg positive patients, the likelihood of response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , interferon, and probably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    depends upon the degree of elevation of the serum aminotransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. As a general rule, treatment with any of these drugs does not result in higher rates of HBeAg seroconversion compared to no treatment in those who have a serum ALT &le;2 X the upper limit of normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prediction of response in HBeAg negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For HBeAg negative patients, prediction of response is less precise. Because of the need for long-term treatment, therapy is recommended only for those with persistent or intermittent elevation in ALT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    substantial histologic abnormalities",
"    <span class=\"nowrap\">",
"     (moderate/severe",
"    </span>",
"    inflammation or bridging",
"    <span class=\"nowrap\">",
"     fibrosis/cirrhosis).",
"    </span>",
"    Interferon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    are generally preferred because long-term treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    is associated with diminishing response due to selection of drug-resistant mutants. Advantages of entecavir and tenofovir are more potent antiviral activity and a lower rate of drug resistance compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    may be a better option than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in patients with renal insufficiency and in those who are at risk for renal insufficiency. While all of these medications require dose reduction according to renal function, entecavir has not been reported to cause renal impairment (",
"    <a class=\"graphic graphic_table graphicRef71024 \" href=\"UTD.htm?15/56/16269\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Failed prior interferon therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who failed to respond to prior interferon therapy can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    with the expectation of a similar response as treatment-na&iuml;ve patients. Because most patients require long duration of treatment, entecavir or tenofovir is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Breakthrough infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Those that develop breakthrough infection due to antiviral drug resistance should be treated with rescue antiviral therapy. Salvage therapy should be initiated promptly once virologic breakthrough is confirmed on repeat testing, prior to biochemical breakthrough, especially in those with worsening liver disease, decompensated cirrhosis, recurrent HBV after transplantation, or immunosuppression. The choice of therapy in patients who developed resistance to",
"    <span class=\"nowrap\">",
"     nucleotide/side",
"    </span>",
"    analogue depends upon which drug was used for initial treatment (",
"    <a class=\"graphic graphic_table graphicRef68845 \" href=\"UTD.htm?17/45/18140\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"        lamivudine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"        telbivudine",
"       </a>",
"      </span>",
"      resistance, addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      or a switch to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      is recommended. Preliminary data suggest that salvage with switch to tenofovir monotherapy may be as effective as add-on tenofovir in suppressing HBV replication.",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      resistance, addition of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"        lamivudine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"        telbivudine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"        entecavir",
"       </a>",
"      </span>",
"      is recommended. However, the durability of response is unclear in patients with prior lamivudine resistance. Entecavir is preferred in patients with prior lamivudine resistance. Case series suggest partial cross resistance between adefovir and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"       \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      resistance,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      is preferred to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      as rescue therapy, and it is preferably added rather than substituted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Compensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with clinically and biochemically compensated cirrhosis, interferon may be used with caution but",
"    <span class=\"nowrap\">",
"     nucleosides/nucleotides",
"    </span>",
"    are safer. Because of the need for long-term treatment,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Decompensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with decompensated cirrhosis should be considered for treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/14\">",
"     14",
"    </a>",
"    ]. Interferon is contraindicated in these patients. In view of the need for long-term treatment, lamivudine and telbivudine are not optimal treatments unless used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    or tenofovir. Adefovir is not recommended because of its weak antiviral activity and risk of nephrotoxicity. Renal function (creatinine every one to three months) should be monitored closely in patients receiving adefovir or tenofovir. Entecavir may be a preferred option. Although a case series reported the occurrence of lactic acidosis in patients with severe liver dysfunction, this is likely a class effect of",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analogs. Furthermore, several larger studies did not observe any clinical cases of lactic acidosis, although lactate levels were not monitored in those studies. Treatment of such patients should be coordinated with a transplant center. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chemotherapy or immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to patients undergoing chemotherapy or receiving immunosuppression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost-effectiveness of various treatment strategies for chronic HBV is incompletely understood. Although several cost-effectiveness analyses have been published, most were conducted before approval of peginterferon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and there was poor quality evidence for many of the parameters used in the models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DOSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are recommended doses of the specific drugs:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa is administered by subcutaneous injection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Standard interferon",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For adults: 5 MU daily or 10 MU three times per week",
"     </li>",
"     <li>",
"      For children: 6",
"      <span class=\"nowrap\">",
"       MU/M(2)",
"      </span>",
"      three times weekly with a maximum of 10 MU",
"     </li>",
"     <li>",
"      Treatment duration for HBeAg positive chronic hepatitis is 16 to 32 weeks",
"     </li>",
"     <li>",
"      Treatment duration for HBeAg negative hepatitis is 12 to 24 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Peginterferon alfa-2a",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For adults: 180 microG once weekly",
"     </li>",
"     <li>",
"      For children: Not approved",
"     </li>",
"     <li>",
"      The manufacturer recommends 48 weeks of treatment for HBeAg positive or negative chronic HBV. [",
"      <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link\">",
"       \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Lamivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is administered orally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The recommended dose for adults with normal renal function without concomitant HIV infection is 100 mg daily. Dose adjustment is required in those with decreased renal function.",
"     </li>",
"     <li>",
"      The recommended dose for children is 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day with a maximum of 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      The recommended dose for those who are coinfected with HIV is 150 mg twice daily (along with other anti-retroviral drugs).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Adefovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    is administered orally. The dose is 10 mg daily. Patients with impaired renal function should have the dosing interval adjusted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Entecavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    is administered orally. The recommended dose is 0.5 mg once daily for nucleoside-na&iuml;ve adults and adolescents older than 16 while it is 1 mg daily for those who have",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance. The dose should be adjusted in patients with a creatinine clearance of &lt;50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Telbivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     Telbivudine",
"    </a>",
"    is administered orally. The recommended dose is 600 mg once daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    is given at a dose of 300 mg daily; the dose needs to be adjusted in renal impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     DURATION AND TREATMENT ENDPOINTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy for the oral drugs is not well-established. Most patients receiving",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analogue therapy will require at least four to five years of treatment, and some may require indefinite treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     HBeAg-positive chronic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endpoint of treatment is HBeAg seroconversion. Patients in whom HBeAg seroconversion has occurred and serum HBV DNA has become undetectable should be treated for at least 12 more months after HBeAg seroconversion has been confirmed (by testing on two occasions at least two months apart) to reduce the rate of relapse. Given that roughly 50 percent of patients enrolled in clinical trials (baseline ALT &gt;1.3x ULN) achieve HBeAg seroconversion after five years of treatment, most patients with HBeAg-positive chronic hepatitis will require several years of treatment. All patients should be closely monitored after discontinuation of treatment as viral relapse may lead to hepatitis flares and hepatic decompensation.",
"   </p>",
"   <p>",
"    Treatment can be continued in patients who have maintained viral suppression but have not seroconverted as HBeAg seroconversion may occur in subsequent years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     HBeAg-negative chronic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endpoint of treatment has not been established. Treatment may be discontinued in patients who have confirmed loss of HBsAg (by testing on two occasions at least two months apart). Given that approximately 5 percent of patients lose HBsAg after five years of continued therapy, most patients with HBeAg-negative chronic hepatitis will require many years of treatment with its associated risks of adverse events, drug resistance, and costs. Long-term outcomes in such patients remain incompletely understood. An illustrative report with long-term follow-up included 33 HBeAg negative patients who achieved undetectable serum HBV DNA and normal aminotransferase levels after four to five years of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/16\">",
"     16",
"    </a>",
"    ]. Adefovir was discontinued, and patients were followed on average for more than five years. Virological relapse was observed in all patients, while 76 percent had a biochemical relapse in the initial months after drug discontinuation. However, with further follow-up, 55 percent had sustained HBV DNA levels of &lt;2000 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    with persistently normal ALT levels. In addition, 13 patients cleared HBsAg. These data need to be confirmed before a recommendation on treatment discontinuation can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Compensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of treatment is to prevent liver failure and HCC. Thus, life-long treatment is generally recommended. It is possible that treatment may be discontinued in those who have lost HBsAg. It is not clear if treatment can be discontinued in HBeAg-positive patients who have achieved HBeAg seroconversion and completed at least 12 months of consolidation therapy, or in patients who have histologic documentation of cirrhosis regression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Decompensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-long treatment is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several new strategies for treatment of HBV continue to be developed. Investigational treatment can be considered in selected patients where such protocols are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23030?source=see_link\">",
"     \"Investigational treatments of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=see_link\">",
"     \"Combination therapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     COUNSELING AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy use of alcohol (&gt;40",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    has been associated with worsening liver disease and an increased risk of HCC. The exact amount of alcohol that can be safely consumed is unclear. Thus, advising patients to be completely abstinent is reasonable in those who have substantial liver injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic HBV should receive appropriate immunizations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link\">",
"     \"Immunizations for patients with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carriers of HBV should be counseled regarding the risk of transmission to others (",
"    <a class=\"graphic graphic_table graphicRef82151 graphicRef55845 \" href=\"UTD.htm?37/1/37916\">",
"     table 7A-B",
"    </a>",
"    ). Patients should be advised regarding prevention of sexual transmission (ie, vaccination of spouses and steady sex partners in individuals with monogamous partners, and safe sex practice including use of condoms in subjects with multiple partners), perinatal transmission, and risk of environmental exposure from blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Household members should be vaccinated if they test negative for HBV serologic markers. HBsAg positive pregnant women should inform their providers so that their infants can receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    and vaccine immediately after delivery. Healthcare workers who are HBeAg positive should not perform invasive procedures without prior counseling and advice from an expert review panel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     MONITORING OF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic screening for hepatocellular carcinoma (HCC) should be performed according to the American Association for the Study of Liver Diseases (AASLD) guidelines. The AASLD guideline for the management of hepatocellular carcinoma, as well as other AASLD guidelines, can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     file://www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are not deemed to be treatment candidates at presentation and those who decide to defer treatment should undergo monitoring of liver biochemical tests, HBV DNA and HBeAg status since liver disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HBV replication may become active later (",
"    <a class=\"graphic graphic_algorithm graphicRef80264 \" href=\"UTD.htm?24/45/25311\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62875 \" href=\"UTD.htm?19/48/20236\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605214278\">",
"    <span class=\"h1\">",
"     ACUTE INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute HBV depends upon the clinical setting. Treatment is mainly supportive and should include appropriate measures to prevent infection in exposed contacts. However, there are known subgroups of patients whose prognosis is relatively worse. These include patients who are immunocompromised, have concomitant infection with hepatitis C virus, have preexisting liver disease, or are elderly.",
"   </p>",
"   <p>",
"    The role of antiviral therapy for such patients remains unsettled since few studies have addressed its benefits during acute infection. Most experience has been in patients who developed reactivation while receiving immunosuppressive therapy. In this setting, prophylaxis with antiviral treatment can help prevent severe reactivation of hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Acute hepatitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not believe that all patients with acute HBV require antiviral treatment since the likelihood of liver failure from acute hepatitis B is less than 1 percent, and in immunocompetent adults, the likelihood of progression to chronic HBV infection is less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/17\">",
"     17",
"    </a>",
"    ]. As a general rule, we treat patients with a severe (such as those who develop a coagulopathy [INR &gt;1.5]) or a protracted course (such as persistent symptoms or marked jaundice [bilirubin &gt;10",
"    <span class=\"nowrap\">",
"     mg/dL]",
"    </span>",
"    for more than four weeks after presentation). We also recommend treating patients with acute liver failure due to hepatitis B to reduce the likelihood of reinfection post-liver transplant. These recommendations are consistent with a 2009 guideline issued by the American Association for the Study of Liver Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients in whom treatment is being offered,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    would all be acceptable options given as monotherapy as the duration of treatment should be short.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    is not preferred because of the weak antiviral activity. Treatment can be stopped after confirmation (two consecutive tests four weeks apart) that the patient has cleared HBsAg. Interferon should be avoided because of the risk of infection and a further increase in hepatic necroinflammation in patients with severe hepatitis or acute liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     CASE ONE, YOUNG ASIAN WITH ACTIVE REPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is a 25-year-old Asian man who is HBsAg (+) and HBeAg (+) with serum HBV DNA of 700 million",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (140 million int.",
"    <span class=\"nowrap\">",
"     unit/mL).",
"    </span>",
"    He has mild inflammation on biopsy. His serum ALT is 100 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    (upper limit of normal 40 int.",
"    <span class=\"nowrap\">",
"     unit/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;This",
"    patient should be considered for therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , or pegylated interferon alfa.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    should not be used unless cost is a limiting factor.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    at the approved dose has weak antiviral activity and has been superseded by tenofovir.",
"   </p>",
"   <p>",
"    The degree of elevation of the serum ALT is particularly important in influencing the decision to treat HBeAg positive patients since it has proven to be one of the most important predictors of HBeAg seroconversion. In one study on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , for example, the rates of HBeAg seroconversion for patients with pretreatment ALT levels within normal, one to two times normal, two to five times normal, and more than five times normal were 2, 9, 21, and 47 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, we consider the degree of elevation of the serum ALT in three categories: normal, between one to two times normal, and more than two times normal. Treatment with any of the approved therapies is unlikely to be successful in achieving HBeAg seroconversion in those with normal or minimally elevated serum ALT. The degree of liver inflammation on liver biopsy is also useful in predicting treatment related HBeAg seroconversion. Increasing data indicate that presence of HBeAg and high serum HBV DNA, lasting four decades or longer, are associated with increased risks of cirrhosis, hepatocellular carcinoma, and liver-related deaths. As a result, treatment may also be considered in patients who remain HBeAg positive after the age of 40, regardless of ALT level.",
"   </p>",
"   <p>",
"    For patients who are contemplating interferon treatment, a test for HBV genotype can be performed. Patients with HBV genotype A are more likely to achieve HBeAg as well as HBsAg seroconversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pros and cons of various treatment options should be discussed with the patient. The main advantages of",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analogues are their side effect profile and ease of administration.",
"   </p>",
"   <p>",
"    The disadvantages of interferon are costs, side effects, and need for parenteral administration but the duration of treatment is finite and interferon is not associated with drug-resistant mutations. All of the oral agents can be considered as a first line therapy.",
"   </p>",
"   <p>",
"    In a young patient like this, the concern is the adverse consequences of drug-resistant mutants and the possibility of more restricted treatment options in the future.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    , despite its higher cost, may be a better first line therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    would be a reasonable alternative in countries in which it has been approved. It is less expensive than entecavir but there is a small risk of nephrotoxicity. Given the young age of the patient, peginterferon should also be considered because of the finite duration of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     CASE TWO, PRESUMED PRECORE VARIANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is a 20-year-old woman who is HBsAg (+), HBeAg (-). Her HBV DNA is 1.2 million",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (approximately 250,000 int.",
"    <span class=\"nowrap\">",
"     unit/mL).",
"    </span>",
"    She has mild portal inflammation, no fibrosis. Her serum ALT is 60 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    (upper limit of normal 40 int.",
"    <span class=\"nowrap\">",
"     unit/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;I",
"    would follow this patient without recommending treatment at this time. Although she has high HBV DNA, she is HBeAg negative, and is likely to be infected with a precore variant. All approved treatments: interferon,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    have a low rate of sustained response in such patients. Because she is young and has only mild histologic changes on liver biopsy, I think it is reasonable to observe her for the time being. A reasonable approach may be to repeat liver function tests every three to six months and consider performing a repeat liver biopsy in a few years.",
"   </p>",
"   <p>",
"    The situation might be different if the patient is 60 years old, repeatedly had a serum ALT that is more markedly elevated or if she had moderate to severe inflammation or bridging fibrosis or cirrhosis on liver biopsy. Because HBeAg negative chronic hepatitis tends to run a fluctuant course, serial testing is needed and treatment should be recommended if she subsequently develops more marked ALT elevation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , or interferon should be considered. Longer duration of treatment will be needed but the optimal duration is unknown as the end-point of treatment has not been defined. Because of the need for long-term treatment,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    are less desirable. Tenofovir has replaced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    because of its more potent antiviral activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     CASE THREE, CHRONIC CARRIER, NORMAL ALT, NORMAL LIVER BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is a 22-year-old man who is HBsAg (+), HBeAg (+), anti-HBe (-). His HBV DNA is 71.5 million",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (approximately 14 million int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    and serum ALT is persistently in the range of 20 to 30 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    (upper limit of normal 40 int.",
"    <span class=\"nowrap\">",
"     unit/L).",
"    </span>",
"    His liver biopsy is essentially normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;I would not treat this patient at this time although his HBV DNA level is high. He is very young, has no significant inflammation on liver biopsy and serum ALT that is normal (which predicts low probability of HBeAg seroconversion to both peginterferon and",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analog).",
"   </p>",
"   <p>",
"    Although antiviral therapy can decrease serum HBV DNA level in this patient, there is no evidence that treating this patient at this stage will improve clinical outcome. Given the low rate of HBeAg seroconversion (&lt;5 percent after one year of treatment), this patient will need to receive treatment for many years and even decades to derive a clinical benefit.",
"   </p>",
"   <p>",
"    The feasibility of achieving this goal must be balanced against the risk of drug resistance. It is also possible that this patient may undergo spontaneous HBeAg seroconversion during the next few years. Thus, I would follow this patient and recheck ALT every three to six months. If his ALT becomes more than two times normal, I would monitor him more frequently and recommend treatment if he does not spontaneously seroconvert after three to six months. I would biopsy this patient if he was 45 years old with similarly high HBV DNA level and consider treatment if HBV DNA level is persistently high or if there is",
"    <span class=\"nowrap\">",
"     moderate/severe",
"    </span>",
"    inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advanced fibrosis on biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     CASE FOUR, DENTAL STUDENT WITH ACTIVE REPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is a 24-year-old who has recently been admitted to dental school. He is HBsAg (+), HBeAg (+), anti-HBe (-). His HBV DNA is 400 million",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (approximately 80 million int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    and serum ALT is 45 (upper limit of normal 40 int.",
"    <span class=\"nowrap\">",
"     unit/L).",
"    </span>",
"    His liver biopsy shows macrovesicular fat, no portal fibrosis. The Dean of the dental school has denied his matriculation pending your advice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations are periodically issued by the Centers for Disease Control and Prevention (CDC) in the United States, the most recent of which were updated in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/18\">",
"     18",
"    </a>",
"    ]. The CDC recommends that chronic HBV infection in itself not preclude the practice or study of medicine, surgery, dentistry, or allied health professions provided that the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthcare providers and students who perform invasive exposure-prone procedures have oversight from an expert panel. The expert panel should include one or more persons with expertise in the provider's specialty, infectious disease and hospital epidemiology, liver disease, the infected provider's occupational health, student health or primary care clinicians, ethicists, human resource professionals, hospital or school administrators, and legal counsel.",
"     </li>",
"     <li>",
"      HBV-infected providers can conduct exposure-prone procedures if a low or undetectable HBV viral load is documented by regular testing at least every six months. A threshold of 1000 int.",
"      <span class=\"nowrap\">",
"       unit/mL",
"      </span>",
"      (5000",
"      <span class=\"nowrap\">",
"       GE/mL)",
"      </span>",
"      or its equivalent is an appropriate threshold. The assay used should have a detection capability as low as 10 to 20 int.",
"      <span class=\"nowrap\">",
"       unit/mL.",
"      </span>",
"      Spontaneous fluctuations above this level may occur and should prompt the HBV-infected provider to abstain from performing exposure-prone procedures while awaiting subsequent re-testing, changing drug therapy, or other reasonable steps.",
"     </li>",
"     <li>",
"      Standard precautions should be rigorously adhered to in all settings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the above, I would advise this patient to reconsider his plans to enter dental school. Because he has high HBV DNA and low ALT levels, the likelihood of him responding (HBeAg loss) to current treatment is low and the chance of him clearing HBsAg is even more remote. He will likely need long-term if not lifelong treatment and be subjected to frequent monitoring throughout his career. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .) The impact of chronic HBV infection with high level viremia on career paths of dental students is different from medical students who can choose career paths that do not involve performance of invasive procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     CASE FIVE, CHRONIC CARRIER, ADVANCED HISTOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is a 50-year-old Asian man who is HBsAg (+), HBeAg (-). His serum ALT is 75 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    (upper limit of normal 40 int.",
"    <span class=\"nowrap\">",
"     unit/L).",
"    </span>",
"    He has moderate hepatitis with bridging fibrosis on liver biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although this patient has only a mildly elevated serum ALT, I would recommend treatment based upon the advanced histologic features on his liver biopsy if his serum HBV DNA level is more than 10,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (&gt;2000 int.",
"    <span class=\"nowrap\">",
"     unit/mL).",
"    </span>",
"    The threshold HBV DNA level for initiating treatment in HBeAg negative patients is unclear because these patients tend to have lower HBV DNA levels than HBeAg positive patients. The benefit of antiviral therapy in preventing adverse clinical outcome: progression to cirrhosis, hepatic decompensation and hepatocellular carcinoma is not as clear in patients with low HBV DNA levels.",
"   </p>",
"   <p>",
"    This patient highlights the importance of liver biopsy in patients with normal or mildly elevated ALT, particularly older patients and those who have been infected for many years. Assuming he has no comorbid conditions or evidence of hepatic decompensation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , or interferon would be reasonable options. Interferon should",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients with decompensated cirrhosis, but it may be used cautiously in patients who have bridging fibrosis and no evidence of clinical or biochemical decompensation. Because of the need for long-term treatment, entecavir or tenofovir is preferred if oral treatment is desired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h1\">",
"     CASE SIX, DECOMPENSATED CIRRHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is a 75-year-old woman who is HBsAg (+) HBeAg (+), and has a serum ALT of 50 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    (upper limit of normal 40 int.",
"    <span class=\"nowrap\">",
"     unit/L).",
"    </span>",
"    Her HBV DNA is 8000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (approximately 1600 int.",
"    <span class=\"nowrap\">",
"     unit/mL).",
"    </span>",
"    She has ascites and known esophageal varices. She is not considered to be a candidate for liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with interferon is not an option for this patient because she has decompensated cirrhosis. I would treat this patient because there is little to lose and suppression of HBV DNA and any accompanying inflammation may be of benefit in a patient with very little hepatic reserve.",
"   </p>",
"   <p>",
"    Given the need for long-term treatment, the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    resistance and the possibility of clinical deterioration due to breakthrough infection must be considered in a patient who is not a transplant candidate. I would also not use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    because of its inconsistent antiviral effects.",
"   </p>",
"   <p>",
"    An important question is whether these patients should receive de novo combination oral antiviral therapy. A trial comparing de novo",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    monotherapy with a combination of entecavir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    found no difference in virologic and serologic responses overall, but combination therapy resulted in more rapid viral suppression and a higher percent with HBV DNA &lt;50 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    at week 96 among the subset of patients with baseline HBV DNA &gt;10",
"    <sup>",
"     8",
"    </sup>",
"    int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/19\">",
"     19",
"    </a>",
"    ]. None of the patients had evidence of genotypic resistance up to week 96. These data indicate that de novo combination therapy is not necessary in most patients but may have a potential benefit in patients with high baseline HBV DNA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=see_link\">",
"     \"Combination therapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With these considerations in mind,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is preferred. Entecavir may be a better choice because patients with decompensated cirrhosis are at risk of renal failure and because this patient is 75. As an alternative,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    can be used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    or tenofovir for rapid viral suppression and to reduce risk of drug resistance. Available data showed that entecavir and tenofovir are well tolerated in this patient population, although one case series reported the occurrence of lactic acidosis in patients with severe liver dysfunction receiving entecavir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations would be the same if this patient is a 44-year-old and is currently on the liver transplant waiting list. Suppressing HBV DNA to undetectable at the time of transplantation will reduce the risk of HBV recurrence post-transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h1\">",
"     CASE SEVEN, REMAINS HBeAg POSITIVE DESPITE LAMIVUDINE FOR ONE YEAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is a 40-year-old man with pretreatment ALT 129 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    and moderate inflammation on liver biopsy. He remains HBeAg positive but HBV DNA is undetectable by PCR after one year of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to think through the treatment plan and all its contingencies prior to beginning any type of therapy for HBV. It is reasonable to continue treatment since longer duration of treatment is associated with an increased probability of HBeAg seroconversion. A problem with longer duration of therapy is the selection of resistant mutants",
"    <span class=\"nowrap\">",
"     (M204V/I",
"    </span>",
"    mutants). These mutants can be detected in 15 to 30 percent of patients at the end of one year of treatment, and in 70 percent of patients at the end of four years of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative options include switching to drugs that are more potent or have lower rates of resistance such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    or to add a drug that is not cross-resistant such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    since it is possible that resistant mutants may already be selected after one year of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have been on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and have had undetectable serum HBV DNA for many years can continue on lamivudine, especially if virus was suppressed to undetectable levels within 6 to 12 months of initiation of treatment. Patients who have only been on lamivudine for one to two years should be switched to other drugs that have lower risk of resistance.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    may be used in patients who had been exposed to lamivudine for a short time and in whom serum HBV DNA is undetectable.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    would be a better option for patients who have been on lamivudine for more than one to two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h1\">",
"     CASE EIGHT, BREAKTHROUGH INFECTION WHILE ON LAMIVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is a 56-year-old woman with HBeAg positive HBV and early cirrhosis on liver biopsy. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    was associated with an initial decline in HBV DNA titers to undetectable levels by PCR assay and normalization of serum aminotransferases. However, after 18 months of treatment, she developed a flare in serum aminotransferases with increasing levels of HBV DNA. She remains HBeAg positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that this patient has developed breakthrough infection with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistant mutation. If possible, specific testing to confirm resistance should be performed, as breakthrough infection may also be due to medication non-compliance. It is important to differentiate hepatitis flares associated with HBeAg seroconversion (which is accompanied by decrease in HBV DNA level) versus flares associated with emergence of drug resistance (which is accompanied by increase in HBV DNA level).",
"   </p>",
"   <p>",
"    In this case, the patient was compliant with medication and had increasing HBV DNA level. Given that she has advanced histologic features, it would be reasonable to add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    10 mg daily or switch to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    300 mg daily. Adefovir or tenofovir is preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    because mutations to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    decrease susceptibility to entecavir and increase the risk of entecavir resistance. In countries where tenofovir is available, tenofovir is preferred to adefovir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h1\">",
"     CASE NINE, ACUTE INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is a 68-year-old man who is hospitalized with low grade fever, abdominal pain, anorexia, and jaundice. Serologic evaluation reveals that he is HBsAg positive, IgM anti-HBc positive, with serum HBV DNA level of 1.5 million",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (approximately 300,000 int.",
"    <span class=\"nowrap\">",
"     unit/mL).",
"    </span>",
"    Serum ALT is 2000",
"    <span class=\"nowrap\">",
"     unit/L,",
"    </span>",
"    total bilirubin is 8.0",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and INR is 1.5. Other causes of liver disease are excluded. The patient is not known to be a carrier for HBV; however, he is bisexual and thus has potential risk factor for HBV carriage. His aminotransferases, INR and total bilirubin rise slightly during the first two days of hospitalization while awaiting the results of the above serology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h2\">",
"     Comment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It would appear that this patient has acute HBV, although reactivation of chronic HBV infection is also possible. It can sometimes be difficult to distinguish acute HBV from exacerbation of chronic hepatitis B based upon serology alone (unless there are previous laboratory tests available). The diagnosis of acute hepatitis B is based upon the detection of HBsAg and IgM anti-HBc (",
"    <a class=\"graphic graphic_table graphicRef60627 \" href=\"UTD.htm?40/60/41932\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69344 \" href=\"UTD.htm?41/25/42398\">",
"     figure 2",
"    </a>",
"    ). However, IgM anti-HBc can also be seen during severe exacerbation of chronic hepatitis B. This patient is more likely to have exacerbation of pre-existing chronic hepatitis B if he has cirrhosis at diagnosis, a family history of HBV, or past history of liver disease. By contrast, acute infection is more likely in patients with a known recent exposure and no prior history of liver disease.",
"   </p>",
"   <p>",
"    A question is whether the patient should be treated with antiviral therapy. The prognosis with acute infection is relatively worse in patients who are immunocompromised, have concomitant infection with hepatitis C virus, have preexisting liver disease, or are elderly. Thus, the patient's advanced age is a risk factor for morbidity (and possibly mortality) from acute infection.",
"   </p>",
"   <p>",
"    Few studies have addressed the benefits of antiviral therapy during acute infection. There are relatively more data with reactivation of infection in patients receiving immunosuppressive therapy. In this setting, prophylaxis with antiviral treatment can help prevent severe reactivation of hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Acute hepatitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not believe that all patients with acute HBV require antiviral treatment since the likelihood of fulminant hepatitis B is less than 1 percent, and in immunocompetent adults the likelihood of progression to chronic HBV infection is less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/17\">",
"     17",
"    </a>",
"    ]. As a general rule, we treat patients with a severe (such as those who develop a coagulopathy [INR &gt;1.5]) or a protracted course (such as persistent symptoms or marked jaundice [bilirubin &gt;10",
"    <span class=\"nowrap\">",
"     mg/dL]",
"    </span>",
"    for more than four weeks after presentation). We also recommend treating patients with fulminant hepatitis B to reduce the likelihood of reinfection post-liver transplant. These recommendations are consistent with a 2009 guideline issued by the American Association for the Study of Liver Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/51/24378/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment would be reasonable given this patient's advanced age and coagulopathy. Interferon should be avoided because of the risk of infection and further increase in hepatic necroinflammation. In patients suspected to have protracted or severe acute hepatitis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    would all be acceptable options given as monotherapy as the duration of treatment should be short. Treatment can be stopped after confirmation (two consecutive tests four weeks apart) that the patient has cleared HBsAg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/1\">",
"      Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/2\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/3\">",
"      European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/4\">",
"      Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/5\">",
"      Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/6\">",
"      Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/7\">",
"      Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/8\">",
"      Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/9\">",
"      Andreani T, Serfaty L, Mohand D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007; 5:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/10\">",
"      Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/11\">",
"      Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/12\">",
"      Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/13\">",
"      Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/14\">",
"      K&ouml;kl&uuml; S, Tuna Y, G&uuml;len MT, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013; 11:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/15\">",
"      Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/16\">",
"      Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/17\">",
"      Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. MMWR Recomm Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/51/24378/abstract/19\">",
"      Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na&iuml;ve patients with chronic hepatitis B. Gastroenterology 2012; 143:619.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3642 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-3011E4F32C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24378=[""].join("\n");
var outline_f23_51_24378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEPATITIS B VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WHO SHOULD BE TESTED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      WHO SHOULD BE TREATED AND HOW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HBeAg-positive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HBeAg-negative patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Choosing among the available options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Interferon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lamivudine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Adefovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Entecavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Telbivudine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Tenofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prediction of response HBeAg positive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prediction of response in HBeAg negative patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Failed prior interferon therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Breakthrough infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Compensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Decompensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chemotherapy or immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DOSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Standard interferon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Peginterferon alfa-2a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Lamivudine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Adefovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Entecavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Telbivudine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Tenofovir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      DURATION AND TREATMENT ENDPOINTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      HBeAg-positive chronic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      HBeAg-negative chronic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Compensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Decompensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      EXPERIMENTAL TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      COUNSELING AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      MONITORING OF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H605214278\">",
"      ACUTE INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      CASE ONE, YOUNG ASIAN WITH ACTIVE REPLICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Comment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      CASE TWO, PRESUMED PRECORE VARIANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Comment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      CASE THREE, CHRONIC CARRIER, NORMAL ALT, NORMAL LIVER BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Comment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      CASE FOUR, DENTAL STUDENT WITH ACTIVE REPLICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Comment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      CASE FIVE, CHRONIC CARRIER, ADVANCED HISTOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Comment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      CASE SIX, DECOMPENSATED CIRRHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Comment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      CASE SEVEN, REMAINS HBeAg POSITIVE DESPITE LAMIVUDINE FOR ONE YEAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Comment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      CASE EIGHT, BREAKTHROUGH INFECTION WHILE ON LAMIVUDINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Comment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      CASE NINE, ACUTE INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      Comment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3642\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3642|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/45/25311\" title=\"algorithm 1\">",
"      AASLD mgmt chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3642|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/43/6838\" title=\"figure 1\">",
"      HBV risk map",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42398\" title=\"figure 2\">",
"      Serology acute and chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3642|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/43/30396\" title=\"table 1\">",
"      Screening HBV high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/48/20236\" title=\"table 2\">",
"      Evaluation chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/32/27149\" title=\"table 3\">",
"      AASLD Rx chronic HBV recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/23/13693\" title=\"table 4A\">",
"      Antiviral Rx HBeAg positive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/56/38796\" title=\"table 4B\">",
"      Antiviral therapy responses among HBeAg-negative patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/13/22749\" title=\"table 4C\">",
"      Comparison approved Rx HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/56/16269\" title=\"table 5\">",
"      Chron HBV dosage adjustment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/45/18140\" title=\"table 6\">",
"      Mgmt antiviral resist HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/24/25995\" title=\"table 7A\">",
"      Prevention transmission HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/10/30891\" title=\"table 7B\">",
"      Counsel prevention HBV recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/60/41932\" title=\"table 8\">",
"      Serologic markers HBV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=related_link\">",
"      Characteristics of the hepatitis B virus and pathogenesis of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6250?source=related_link\">",
"      Clinical significance and molecular characteristics of common hepatitis B virus variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=related_link\">",
"      Combination therapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23030?source=related_link\">",
"      Investigational treatments of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25750?source=related_link\">",
"      Telbivudine in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=related_link\">",
"      Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_51_24379="Etiology of arteriovenous fistulas";
var content_f23_51_24379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of arteriovenous fistulas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vessel injury*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Traumatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iatrogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Femoral catheterization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Post-surgical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Following biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hemodialysis vascular access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lumbar spine surgery (leading to aortocaval or iliocaval fistula)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patent ductus arteriosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary AV fistula (Osler-Weber-Rendu syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Klippel-Trenaunay syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system or vertebral fistulas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiomas",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AV: arteriovenous.",
"     <br>",
"      * Most common etiologies.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24379=[""].join("\n");
var outline_f23_51_24379=null;
var title_f23_51_24380="Incidence cannabis use";
var content_f23_51_24380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated cumulative (lifetime) incidence of cannabis use N = 54,068",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Country",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        SE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Belgium",
"       </td>",
"       <td>",
"        10.4",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colombia",
"       </td>",
"       <td>",
"        10.8",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        France",
"       </td>",
"       <td>",
"        19.0",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Germany",
"       </td>",
"       <td>",
"        17.5",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Israel",
"       </td>",
"       <td>",
"        11.5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Italy",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Japan",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lebanon",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mexico",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Netherlands",
"       </td>",
"       <td>",
"        19.8",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New Zealand",
"       </td>",
"       <td>",
"        41.9",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nigeria",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        People's Republic of China",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Africa",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spain",
"       </td>",
"       <td>",
"        15.9",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ukraine",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        US",
"       </td>",
"       <td>",
"        42.4",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Degenhardt, L, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: finding from the WHO World Mental Health Surveys. PLoS Med 2008; 5:1053.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24380=[""].join("\n");
var outline_f23_51_24380=null;
var title_f23_51_24381="Long term outcome streptokinase";
var content_f23_51_24381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benefit from streptokinase persists for 10 years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 264px; background-image: url(data:image/gif;base64,R0lGODlhdwEIAeYAAP///4CAgAAAAP+AgEBAQMDAwICZzCAgIBBAn/+goAAzmTAwMKCz2aCgoHBwcPDz+fDw8P8AANDQ0FBQULCwsBAQEEBms5CQkHCNxiBNpuDg4P/AwMDN5mBgYLDA3zBZrP9wcODm8/9AQP8QEP/w8P8gIFBzuWCAv9DZ7P8wMJCm0//g4P/Q0P9gYP9QUP+wsP+QkN8WI4CPr9+Gk4ApXICJvC8pfIBQbwAmcq+AoGBmc38ZTL+AgO8yOTA/X7Cwzw8vjwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAB3AQgBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7EBRKDEA0BDRCDFAEXGt/u78QSAQIEgwv0AguCDvkVFe3wAgrMRUAAPUEUBEwAMEEABQgCKgC4IMDBwIsYZRU4CGBegI4CAmysN3JQgQAoA/AYwHLAhowwY24qCfKjx5I0AZxE6eNGSxEDZAodKokmRYv8LkjIByDhQkMyEDwQxJKo1auIJFBcUACCBgEHChwQ0G4shYYNDgXAgYFqUKxw/7EWNCigAIAGYw+kBSDhXgWLanUg4ACgatzDiCehNPCh8NvEkCMnQgnggwEQICRr3iyIMgcEMyIk4Ew6MWUAGCwkEF26NdbTDxB4WD3atW2ZpwEwaEz7tm+MuR8oCAEgwYjHv5N/yw3ghApBLFK4IKG8OjfmHjIMIuEiBQvr4K8xB4AABaEBx1u2fBm+vbLxGNoSegFC/QCg7vMfG48CASPD+gUYzHgAZODBIgAKqCAvBKpwAoLILSjhLQSGoMBUiSQ44YazEFjZcxlGyOGIrnjIgAIMJIIZiSy+4qFuKCJi3Hct1pjKizCmeMiMNnLowF4XfFQKjjnKOAKNPQoIQf8BC3RQQAET1DOkkImcqKMh6FGXZIAb0WVQB6YQKYiViLSQgpZbuqdBAAcQgNIF6EzZCJmHmIlmmu1JABAqYg5CpyF24umeBFESQABgpPTpJwIWEFcICSm0IGh7Y9ElZaJUNvIABggYYAikkk5qnUKqKFoIBx98QBghoIpa3QSInmKqIQYggAGGgpBwnKvJdVCBoYeGmWkkIVggGyEsjFAbr7bNZdClo8yKiAcIXAlAsss+usG2MLjEbJLSItLfg4Mki5kI6I4QwbroitACft9e1VddB1wgbCYPfGACrgnUt+0GKxyiYbwyLeBPAQ5AK0q4iTxgwge4NjIwwTA5RMD/SQqHwrAiJ5T3yMQUY1TBBQRQcACYcnLCQLWOgBzyQPPQZVfKnGSXgbWIDNBCwC/LRPIEFMg67CYMZHCzIhu4EEEKMPDc80DqALCmODR/UvTRiZCQQAsjlAACkk+7c4CQBDyFKSlXMxDxIS+0UEIJLbwQ9jd1dZYxKBtPwoAFCpiggqOJsABCCSO0kMCdc1tzMgQQNHnvKQ8wYAICGZzgwdqFrABDChGIkG3i08Rs0Mxnr8IBYwpYtioiKyRQggjsgT5NA2UHLQk5AdgOAO7nIJL3Jg94cEIGjOJcCHouOC27Mw3sNUnj+VQkyD0F6aPW0K2EoILRBnTv/fc10LBD/w6IL59MlJUcBcBYGjjFkEMmpeSmLQxg8P393WMARAwimm8MXk8KRyTmYZGCnCQkNYkfSuY3DAzYoAcl+Jz/iOEsjjziK/SoQF08kkBD/A4WFjiB62A3wf+lxBySkAdeBDAR6SXlesWITYqQp7wSAkMdU5NEA6Akva+EhX0wLMZnzEMCEEQABOWzoS74UZcJoAwSBhnbIFaoF99hDxjbw9AKXLArJfaiAh3gSgDu9okPysIEJiDEBkRQArl5URd1uVgHyOgJM8biARkA0SCMk5k34oIACzhAQ+xVtWL0Z3XQSYEIkujHV0hAg/mIU+mQsbK1kYBrYGukRqj2uGScwP8Ch4BBBGCgSVlAIGFAE9oy8iWfQiSrBYws5SkqqLtoXZEYIbAV/gzwAxF4R5atQGDj6NgJO9bCA7vkFApAkB77gECCwOxEKjtiNltaY2UhoI99WPI2aEYzEx1oEwEO0KZY4e2WzsAAxBLhugh+sxMVfNYkq3GCxiiind58py+MCYwPkOue3dTnMPj5C1Y2Ap8CBQZBf5FL48nobW5M6C4W+ov+ONRIfZQoJCRZyGus7ASYY10KUlBDjSpCLAHgqMbQOQ2HZQCRi2BmRE2qCA0UpAK1POc3VGCrR7xgBBml6SKeNE9uFOsD5mnECkZaUo0G8KmctOY7DKAATzmCmS3/AcFMBeolS3XSHSj4QKMcoU2WjCB5Ej1hSpwn1YBwSo+PKOIISClUPrF0GxzIwL4ksYHXZTKaDYCkBdsqkAd07KIIikD/SknODD6RsANZWVIjwQI2xg6YDmGhAx67sLt6A5uUgAFQY6nEuiwgAOjr6EDUGVKlcjGfNmxSzMy5UqHU0xIvCCgwL0BI1V7En5dAqB8vkFPfDsSgwdWtEgtyAAfsqagwaWgmhFtCCTjgHgLgbG2JYlFNtFM9l00cOQpCTE5QdBor2+t063Ofxb6MiQohHWSF4rBjccJlIQNk71QJF2qpNxP4pZhKv3qV+qoNwEBhSXgJRgDrAitYxh2K/wc+gIATTJYSG/iJe3kVRy+VdxPn1QYKOvaBA18iwHUdRIi3ETkKW9gS7d2mVr/VAefeyLNXGTECPnCgSWR4m2YN6qTmsoD9brQccBIE7wbcGRxjJXIVbi0llkpSXlHAAWP5cCGgd1N0UI8pQWzNAyzw0k7I1FUUCOdgG7ERfRjQfQ0pbkecfBieWnUTPxVykoic5I3eI5Bg4iAHBbGTMdL5MGFFKieo3NQW1fi5G/XVWBYAAUEjkNDyOzRiagXXTGB1AM/sUfPSh8CGrMOFAugtIVaMkbxaQMqTKGsJUrDgDaV2Eg3IB5ME0AAfioUsYU6OYVn2CdGSkEQAfFJUHf/hAA1K8S55YeuqNR2ZCdsKcJsgAXp2NqIKajkTrJbJiPvWY05cMgKw3FA51kpg8Dxge3mE9SRWwLUBkHZ54baKB0yggBdzYo1zXZC3252fEHCqxJ3YQAraKKCEGUp6EXZP0SwAU0y0YMPhOS3BFVQrE2D7xBi3DgTatHEFbUoBtwJwyH9TQe3qtEUhmNydK4Hi3zicAB1gchmpHR4OkBmxEvPctu79Gz3xt0cTr7gjMuwCdK2rcyJwwQAOx/IOJEQAy97uljr+cUqQYFsJGIDSXEB111jsAI6L+IhOnnJzJ2DsZedMXcA4xpLXKOad+oTW4E50qwQy1XO0u418biD/UOw9Ai6oNVwKUIEFaGBkgkd6T0NxyZWTKN/KCUGqur6Jml+e5yPiVLk7EWMFpwnz1qFWK/+tHniBC/Qk0vwHON95ywtErSiRttZDJvpQeF4gXZWn2kWlelCU3ltCeVK9nsRA6FJM9rS3xI9Z4nqhwK8j38YE6vXTe9/bXmwVCECzq9lZ2flX3jRP8Hpg8kiDVCDrLwddfUe/ielT//vbIOrRzY+A/xof/9hwSg02Tc43N/MnCr+nDQ1RFx1AfrtnPudnfOoHZKAGW9KQahdTd8PXMwfoCfZHgUZkgdBgMQVQNpE3NypgT6vQG9ngKxUwFroXfzYUGxeWCix4DRDQ/xB/sX82dAL/tIKscQ1GxxeQ9oAl1B/oJwo3SA0MpIEF6D/+tEsGgAH0BwpLCA0SQAAvaCi/coKJczpSWCsgRQqrwV6h5gxdQhc45YVe5FJK1wn9whIhCA0/UiqwZz48tXpkGIRkxRJutC3QATCzIAEBBH87R1NHVYNKyIeKACmdwzlBsS4AsAFL03elAF9rZoQJRVUzNwpXKDBHBB1ysy66ciSz8Csh0VxsWEphNValUIbgZQir0TkDQCPswoiwUBcCUGkOKINC9VamEIfrhyXqsi6j8XQR8FeuYDETsADZdwnb9zJ55X+toCWC0zkAsC5Kcyaz4AC5YxAxqAhL8v9U6LBkVpRihDBsQGcK95EAG9ACipWNEQAAnBMqtCABhnhSXWUXX2Y9HnSHjZQdFOcKa7QuJfAWkrgC6iKCpgABQZJ7kTCOuUYWcHZ9OpFp6GgIDyCG0ScQlSJ8ktAB2ZVAg3aRCwSQpRQCHWMASegN8aVsk4BB7WBp2BONskN46/gNm3UJIoky6vNC/5iRi5B0GTGRIPkIXQIQvgZEQSmUirCRFdaR3BARwEJbjFAQsUJF4WiTE6SSndKSioOSAySWAoWTAYFl7LaBTikIKhAj7zBwarmWReIOhFiIqyiXJ2I/90OFv8GVflQ/u5QBrigNDXZzEPaEchkJG1lVYDn/DB3mVXGZmItQLIVXGn4pUQIplcbAQA7Qi4comZywmCwJCdpjACbWCalxCWvSJijhjHcJmo1AmTk5JgpQmwoASo7AN7mpAJeQhnRBlotwmUJlM+toIYMBACjgKZsSQuYRAgbgAanhKXlVVRxwOijAAISxbxYAIrppCUvSJDD5mrD5CFeDP6vTlnpIYYyBACHAAbVpLCiyMrfJAFSFAFXlAX2DASgHAN15Cfg4EeH4meMJCoD5PavDiYSAAvuJnyrgnp6Cn57SnVTVY/w2FRTGn7yJCQvgjQYhZwI6oKlwIrgJAO1ZVQDgoA56oiYqoQqwKt2pm/1pCXG0ABPgmXUE/5wgCgkZcJsGYAKgRDkcwG8okKIpyjcekJwtypb32TcYmgmZ5Y3PaAnCCaIxV5t5hJwfoABHQ6QmSi0KoAJUtTqc0jdTEaOVsIANUKPimaPYoAGwAgEls6ZsehtTOqe6MA8A4AAFFKWVUKd2igt4aigAIKiR+afUEKj1QKiIaajaIDqQuaiMig2OepTlF6kB4qeW6g6YmqnesKmceh04+qlW4amimg2kWqriEaqoihuquqowcaquGjqtGqsXAau0Cg22eqvOkKu6ygy82qvvMavAqqnCOqzLgDtCYo7BZqwY0X7jND344I+F8KvMGgtjwUkVKWfUWq2usBSNtRA0qf9AhsatGNFmu1YOCFSShSYS5HoRS1EPHvGTqdauVmEW91AASwls9DoU81IBe6GV+xqw+7quuFewBnuwCJuwCruwDNuwDvuwEBuxEjuxFPuw8kUUhlaxGrtAbrKxGmsoHluxIBuyFDuyJCuxzTeqxfoInrqpLbuyjrCtFAKzjfCysWCzN0uzvqqzwcmziuCyPjsZQXuOrzG0y9oKQCsLOHsV+gcLTfsKT9sKUSu1F0u1Anu1WJu1Wru1XNu1Xvu1AaKsraABQdJnjoSvr4CsaYtkOlcKAqRk5WBkMNGPr+As0soK7We0guCsB+AKXBYRbRsK8mBBdBsT2eoKDzFydeP/Ctilt+uDdU7LFAakCnMhJYf7qul6aa/AlKwQAH+huargrWNho6UAPYDGCjQRrphrE6DLCurTCkuhDq2LCuZ6DwFKChAgaZG0CqmbuY7LC/KqaqvADy7HJ11ltO/aQatAER9harzLEcEbE/lahKjQEGPDrqygAU/Sk9RrCva6uKuQa1xhu6G7FV0xvTIBsMvoJb+rvKvQr7d7ic42tBVkF+oLtvibv/q7v/zbv/77vwAcwAI8wMzwJABBiN1LwNEwD/UAAf4QuArsDIoru/ZSabWzD4bSAeJwEhKwQxNhKDYWwb+QEJM2PeF3D+IwNs3Wt/OgQQEgkt7IFSIMDHMhYQ7v+sIIhDBayELzYDsNMQHYO8O+QBMjkRIF4BQUcA8gMTO5i10eKsS2kBP+sEMXgK65MxZLLAgdcAEIM69QzAs5QShR9BD30FhZ3BEatINfvMZs3MZu/MZwHMdyPMf9GwgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among patients entered into GISSI-1 who were treated within one hour of symptoms of a myocardial infarction and were discharged alive, life-table estimates show that the 10-year survival of patients allocated to streptokinase was greater compared to the control group. Most of the survival benefit was seen early, due to the reduction in in-hospital mortality; there was an insignificant trend toward further benefit after discharge.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Franzosi MG, Santoro E, De Vita C, et al. Circulation 1998; 98:2659.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24381=[""].join("\n");
var outline_f23_51_24381=null;
var title_f23_51_24382="Contents: Adult Primary Care and Internal Medicine";
var content_f23_51_24382=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Adult Primary Care and Internal Medicine",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult Primary Care and Internal Medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?35/3/35903\">",
"         Adult orthopedics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/32/37390\">",
"         Adult procedures",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/59/43966\">",
"         Adult signs and symptoms",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/21/22878\">",
"         Anxiety disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/53/38749\">",
"         Cancer survivorship",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?29/14/29933\">",
"         Complementary medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/63/4095\">",
"         Depressive disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/5/22608\">",
"         General medical issues in women",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?16/2/16418\">",
"         General medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?2/25/2462\">",
"         Genetics basic science",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?34/8/34945\">",
"         Geriatric medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?7/56/8064\">",
"         Laboratory medicine",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?25/59/26558\">",
"         Lipid disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/51/37694\">",
"         Medical consultation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?29/47/30461\">",
"         Nutrition and diet",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/27/41394\">",
"         Office gynecology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/47/38653\">",
"         Primary care calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?20/47/21242\">",
"         What's new in primary care internal medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?30/63/31731\">",
"         Primary care cardiology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/57/18321\">",
"         Primary care dermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?24/35/25137\">",
"         Primary care endocrinology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/53/5982\">",
"         Primary care ENT",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/5/18514\">",
"         Primary care gastroenterology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/24/5504\">",
"         Primary care hematology",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?11/17/11540\">",
"         Primary care infectious disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?30/42/31407\">",
"         Primary care nephrology urology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?23/1/23583\">",
"         Primary care neurology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?25/53/26463\">",
"         Primary care oncology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/33/8734\">",
"         Primary care ophthalmology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/16/27919\">",
"         Primary care pulmonary disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/6/5231\">",
"         Primary care rheumatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/15/21758\">",
"         Psychiatric disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?11/19/11583\">",
"         Screening preventive medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/26/10670\">",
"         Spinal disease and back pain",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/25/17822\">",
"         Substance use disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?43/18/44333\">",
"         Venous disease",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-F06B6384FE-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f23_51_24382=[""].join("\n");
var outline_f23_51_24382=null;
var title_f23_51_24383="TEE LA appendage thrombus";
var content_f23_51_24383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/56080/teethla1_conv.mp4?title=TEE+LA+appendage+thrombus\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial appendage thrombus seen on TEE",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows a stationary thrombus in the left atrial appendage. The mitral leaflets do not appear to open normally, suggesting the presence of mitral stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_51_24383=[""].join("\n");
var outline_f23_51_24383=null;
              